非定型パーキンソニズム

出版社： 文光堂
著者：
発行日： 2019-05-18
分野： 臨床医学：外科  >  脳神経外科学
ISBN： 9784830615474
電子書籍版： 2019-05-18 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

8,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

8,800 円(税込)

購入する

商品紹介

非定型パーキンソニズムは主に進行性核上性麻痺，大脳皮質基底核変性症，レヴィ小体型認知症，多系統萎縮症などのパーキンソン病に似た症状を示す疾患群で，この領域は基礎，臨床ともに進歩が著しい．本書は，非定型パーキンソニズムの最新の研究動向，現在の診療における課題を提示しつつ，日常診療に役立つ内容となっている．本領域の専門以外の神経内科医も知っておくべき最新の情報がふんだんに盛り込まれている．

目次

  • I　総　論
    　1．本領域における概念の変化
    　2．症候の理解と電気生理
    　3．疫学，疫学研究の方法
    　4．非定型パーキンソニズムの主な症候
    　5．非定型パーキンソニズムの現状と課題

    II　各　論
    　1．多系統萎縮症
    　2．進行性核上性麻痺
    　3．大脳皮質基底核変性症
    　4．神経変性タウオパチーの分子遺伝学と臨床病理
    　5．Globular glial tauopathy
    　6．レヴィ小体型認知症
    　7．正常圧水頭症

    III　病態解明と治療法の確立に向けて
    　1．治療戦略
    　2．動物モデル
    　3．臨床試験デザイン

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.6 掲載の参考文献
1) Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy : The movement disorder society criteria. Mov Disord 2017 ; 32 : 853-864.
PubMed
2) Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013 ; 80 : 496-503.
PubMed
3) McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 2017 ; 89 : 88-100.
PubMed
4) the MoDiMSA meeting 2018 (Hong Kong)
 
5) Wong YC, Krainc D. α-synuclein toxicity in neurodegeneration : mechanism and therapeutic strategies. Nat Med 2017 ; 23 : 1-13.
 
6) Woerman AL, Watts JC, Aoyagi A, et al. α-synuclein : multiple system atrophy prions. Cold Spring Harb Perspect Med 2018 ; 8 (7).
 
7) Falcon B, Zhang W, Murzin AG, et al. Structures of filaments from Pick's disease reveal a novel tau protein fold. Nature 2018 ; 561 : 137-140.
PubMed
8) Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease : a randomized clinical trial. JAMA Neurol 2018 ; 75 : 1206-1214.
 
9) West T, Hu Y, Verghese PB, et al. Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer's disease and other tauopathies. J Prev Alzheimers Dis 2017 ; 4 : 236-241.
PubMed
10) Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : report of the NINDS-SPSP international workshop. Neurology 1996 ; 47 : 1-9.
 
11) Shimohata T, Kanazawa M, Yoshida M, et al. Clinical and imaging findings of progressive supranuclear palsy with predominant cerebellar ataxia. Mov Disord 2016 ; 31 : 760-762.
PubMed
12) Koga S, Josephs KA, Ogaki K, et al. Cerebellar ataxia in progressive supranuclear palsy : An autopsy study of PSP-C. Mov Disord 2016 ; 31 : 653-662.
PubMed
13) Mathew R, Bak TH, Hodges JR. Diagnostic criteria for corticobasal syndrome : a comparative study. J Neurol Neurosurg Psychiatry 2012 ; 83 : 405-410.
PubMed
14) Koga S, Kouri N, Walton RL, et al. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome : a distinct clinicopathologic subtype. Acta Neuropathol 2018 Jun 20. doi : 10.1007/s00401-018-1878-z. [Epub ahead of print]
 
15) Riku Y, Watanabe H, Mimuro M, et al. Non-motor multiple system atrophy associated with sudden death : pathological observations of autonomic nuclei. J Neurol 2017 ; 264 : 2249-2257.
PubMed
16) Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. Natural history of pure autonomic failure : A United States prospective cohort. Ann Neurol 2017 ; 81 : 287-297.
PubMed
17) Aoki N, Boyer PJ, Lund C, et al. Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration : frontotemporal lobar degeneration associated with α-synuclein. Acta Neuropathol 2015 ; 130 : 93-105.
 
18) Ouchi H, Toyoshima Y, Tada M, et al. Pathology and sensitivity of current clinical criteria in corticobasal syndrome. Mov Disord 2014 ; 29 : 238-244.
PubMed
19) Alexander SK, Rittman T, Xuereb JH, et al. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 2014 ; 85 : 925-929.
PubMed
20) Day GS, Lim TS, Hassenstab J, et al. Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology 2017 ; 88 : 1273-1281.
PubMed
P.10 掲載の参考文献
1) Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease : a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992 ; 55 : 181-184.
 
2) Koga S, Aoki N, Uitti RJ, et al. When DLB, PD, and PSP masquerade as MSA : an autopsy study of 134 patient. Neurology 2015 ; 85 : 404-412.
PubMed
3) Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006 ; 66 : 41-48.
PubMed
4) Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits : neural substrates of parallel processing. Trends Neurosci 1990 ; 13 : 266-271.
PubMed
5) Matsuo H, Takashima H, Kishikawa, M et al. Pure akinesia : an atypical manifestation of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1991 ; 54 : 397-400.
PubMed
6) Williams DR, Holton JL, Strand K, et al. Pure akinesia with gait freezing : a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007 ; 22 : 2235-2241.
PubMed
7) Pramstaller PP, Salerno A, Bhatia KP. et al. Primary central nervous system lymphoma presenting with a parkinsonian syndrome of pure akinesia. J Neurol 1999 ; 246 : 934-938.
PubMed
8) Little S, Brown P. The functional role of beta oscillations in Parkinson's disease. Parkinsonism Relat Disord 2014 ; 20 Suppl 1 : S44-48.
 
9) Djuric-Jovicic M, Petrovic I, Jecmenica-Lukic M, et al. Finger tapping analysis in patients with Parkinson's disease and atypical parkinsonism, J Clin Neurosci 2016 ; 30 : 49-55.
PubMed
10) Ling H, Massey LA, Lees AJ, et al. Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. Brain 2012 ; 135 : 1141-1153.
PubMed
11) Leiguarda RC, Merello M, Nouzeilles MI, et al. Limb-kinetic apraxia in corticobasal degeneration : clinical and kinematic features. Mov Disord 2003 ; 18 : 49-59.
PubMed
12) Tashiro K, Ogata K, Goto Y, et al. EEG findings in early-stage corticobasal degeneration and progressive supranuclear palsy : a retrospective study and literature review. Clin Neurophysiol 2006 ; 117 : 2236-2242.
PubMed
13) Valls-Sole J. Assessment of excitability in brainstem circuits mediating the blink reflex and the startle reaction. Clin Neurophysiol 2012 ; 123 : 13-20.
PubMed
14) Valls-Sole J, Valldeoriola F, Marti MJ, et al. Distinctive abnormalities of facial reflexes in patients with PSP. Brain 1997 ; 120 : 1877-1883.
 
15) Kujirai T, Caramia MD, Rothwell JC, et al. Corticocortical inhibition in human motor cortex. Journal of Physiology 1993 ; 471 : 501-519.
PubMed
16) Tokimura H, Di Lazzaro V, Tokimura Y, et al. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol 2000 ; 523 : 503-513.
PubMed
17) Di Lazzaro V, Oliviero A, Tonali PA, et al. Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. Neurology 2002 ; 59 : 392-397.
PubMed
18) Brusa L, Ponzo V, Mastropasqua C, et al. Theta burst stimulation modulates cerebellar-cortical connectivity in patients with progressive supranuclear palsy. Brain Stimul 2014 ; 7 : 29-35.
PubMed
19) Hanajima R, Ugawa Y, Terao Y, et al. Ipsilateral corticocortical inhibition of the motor cortex in various neurological disorders, J Neurol Sci 1996 ; 140 : 109-116.
PubMed
20) Frasson E, Bertolasi L, Bertasi V, et al. Paired transcranial magnetic stimulation for the early diagnosis of corticobasal degeneration. Clin Neurophysiol 2003 ; 114 : 272-278.
PubMed
21) Benussi A, Dell'Era V, Cantoni V, et al. Discrimination of atypical parkinsonisms with transcranial magnetic stimulation. Brain Stimul 2018 ; 11 : 366-373.
PubMed
22) Ugawa Y, Day BL, Rothwell JC, et al. Modulation of motor cortical excitability by electrical stimulation over the cerebellum in man. J Physiol 1991 ; 441 : 57-72.
 
23) Shirota Y, Hamada M, Hanajima R, et al. Cerebellar dysfunction in progressive supranuclear palsy : a transcranial magnetic stimulation study. Mov Disord 2010 ; 30 ; 25 : 2413-2419.
 
24) von Lewinski F, Schwan M, Paulus W, et al. Impairment of brainstem implicit learning paradigms differentiates multiple system atrophy (MSA) from idiopathic Parkinson syndrome. BMJ Open 2013 ; 3 : e003098.
PubMed
25) Wittstock M, Pohley I, Walter U, et al. Interhemispheric inhibition in different phenotypes of progressive supranuclear palsy. J Neural Transm (Vienna) 2013 ; 120 : 453-461.
PubMed
26) Suppa A, Marsili L, Di Stasio F, et al. Primary motor cortex long-term plasticity in multiple system atrophy. Mov Disord 2014 ; 29 : 97-104.
PubMed
27) Suppa A, Di Stasio F, Marsili L, et al. Primary motor cortex LTP/LTD-like plasticity in probable corticobasal syndrome. J Neurophysiol 2016 ; 115 : 717-727
 
28) Conte A, Belvisi D, Bologna M, et al. Abnormal cortical synaptic plasticity in primary motor area in progressive supranuclear palsy. Cereb Cortex 2012 ; 22 : 693-700.
PubMed
29) Bologna M, Suppa A, Di Stasio F, et al. Neurophysiological studies on atypical parkinsonian syndromes. Parkinsonism Relat Disord 2017 ; 42 : 12-21.
PubMed
P.16 掲載の参考文献
1) Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy : a cross-sectional study. Lancet 1999 ; 354 : 1771-1775.
PubMed
2) Paul S, Hwang JK, Kim HY, et al. Multiple biological properties of macelignan and its pharmacological implications. Arch Pharm Res 2013 ; 36 : 264-272.
 
3) Low PA, Reich SG, Jankovic J, et al. Natural history of multiple system atrophy in the USA : a prospective cohort study. Lancet Neurol 2015 ; 14 : 710-719.
PubMed
4) Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964 ; 10 : 333-359.
PubMed
5) Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy : Richardson's syndrome and PSP-parkinsonism. Brain 2005 ; 128 : 1247-1258.
PubMed
6) Williams DR, Holton JL, Strand K, et al. Pure akinesia with gait freezing : a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007 ; 22 : 2235-2241.
PubMed
7) Kanazawa M, Shimohata T, Toyoshima Y, et al. Cerebellar involvement in progressive supranuclear palsy : A clinicopathological study. Mov Disord 2009 ; 24 : 1312-1318.
PubMed
8) Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy : The movement disorder society criteria. Mov Disord 2017 ; 32 : 853-864.
PubMed
9) Kawashima M, Miyake M, Kusumi M, et al. Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord 2004 ; 19 : 1239-1240.
 
10) Takigawa H, Kitayama M, Wada-Isoe K, et al. Prevalence of progressive supranuclear palsy in Yonago : change throughout a decade. Brain Behav 2016 ; 6 : e00557.
 
11) Yoshida K, Hata Y, Kinoshita K, et al. Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes : a forensic autopsy series. Acta Neuropathol 2017 ; 133 : 809-823.
PubMed
12) Rebeiz JJ, Kolodny EH, Richardson EP, Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968 ; 18 : 20-33.
PubMed
13) Osaki Y, Morita Y, Kuwahara T, et al. Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand 2011 ; 124 : 182-187.
 
14) Boeve BF, Maraganore DM, Parisi JE, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999 ; 53 : 795-800.
PubMed
15) Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 ; 80 : 496-503.
PubMed
16) Ouchi H, Toyoshima Y, Tada M, et al. Pathology and sensitivity of current clinical criteria in corticobasal syndrome. Mov Disord 2014 ; 29 : 238-244.
PubMed
17) Alexander SK, Rittman T, Xuereb JH, et al. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 2014 ; 85 : 925-929.
PubMed
18) 朝田隆. 厚生労働科学研究費補助金認知症対策総合研究事業. 都市部における認知症有病率と認知症の生活機能障害への対応, editor 2013.
 
19) McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 2017 ; 89 : 88-100.
PubMed
P.21 掲載の参考文献
1) Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy : an analysis of 230 Japanese patients. Brain 2002 ; 125 : 1070-1083.
PubMed
2) Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015 ; 30 : 1591-1601.
PubMed
3) Baschieri F, Calandra-Buonaura G, Cecere A, et al. Iodine-123-meta-iodobenzylguanidine myocardial scintigraphy in isolated autonomic failure : Potential red flag for future multiple system atrophy. Front Neurol 2017 ; 8 : 225.
PubMed
4) Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. Natural history of pure autonomic failure : A United States prospective cohort. Ann Neurol 2017 ; 81 : 287-297.
PubMed
5) Iranzo A, Santamaria J, Valldeoriola F, et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 2017 ; 82 : 419-428.
PubMed
6) Miyamoto T, Miyamoto M, Suzuki K, et al. 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep 2008 ; 31 : 717-723.
 
7) Ling H, Asi YT, Petrovic IN, et al. Minimal change multiple system atrophy : an aggressive variant? Mov Disord 2015 ; 30 : 960-967.
PubMed
8) Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy : The movement disorder society criteria. Mov Disord 2017 ; 32 : 853-864.
PubMed
9) Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 ; 80 : 496-503.
PubMed
10) Leigh R, Zee D. Disorders of Ocular Motility with Disease Affecting the Basal Ganglia, Cerebral Cortex, and in Systemic Conditions. In : Leigh R, Zee D, eds. The Neurology of Eye Movements (Contemporary Neurology Series). New York : Oxford University Press, 2015 : 916-1023.
 
11) Hanuska J, Bonnet C, Rusz J, et al. Fast vergence eye movements are disrupted in Parkinson's disease : A video-oculography study. Parkinsonism Relat Disord 2015 ; 21 : 797-799.
PubMed
12) Dubois B, Slachevsky A, Litvan I, et al. The FAB : a Frontal Assessment Battery at bedside. Neurology 2000 ; 55 : 1621-1626.
PubMed
13) Day GS, Lim TS, Hassenstab J, et al. Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology 2017 ; 88 : 1273-1281.
PubMed
14) Deramecourt V, Lebert F, Debachy B, et al. Prediction of pathology in primary progressive language and speech disorders. Neurology 2010 ; 74 : 42-49.
PubMed
15) Josephs KA, Duffy JR, Strand EA, et al. The evolution of primary progressive apraxia of speech. Brain 2014 ; 137 : 2783-2795.
PubMed
P.27 掲載の参考文献
1) Dodge R. Five types of the eye movement in the horizontal meridian place of the field of regard. Am J Physiol 1903 ; 8 : 307-329.
 
2) Hikosaka O, Takikawa Y, Kawagoe R. Role of the basal ganglia in the control of purposive saccadic eye movements. Physiol Rev 2000 ; 80 : 953-978.
PubMed
3) Sharma R, Hicks S, Berna CM, et al. Oculomotor dysfunction in amyotrophic lateral sclerosis. Arch Neurol 2011 ; 68 : 857-861.
PubMed
4) Corin MS, Elizan TS, Bender MB. Oculomotor function in patients with Parkinson's disease. J Neurol Sci 1972 ; 15 : 251-265.
PubMed
5) Shibasaki H, Tsuji S, Kuroiwa Y. Oculomotor abnormalities in Parkinson's disease. Arch Neurol 1979 ; 36 : 360-364.
PubMed
6) MacAskill MR, Andersen TJ. Eye movements in neurodegenerative diseases. Curr Opin Neurol 2016 ; 29 : 61-68.
 
7) 廣瀬源二郎. Q&A-神経科学の素朴な疑問 年を取ると寄り目ができなくなるのはなぜですか? Clin Neurosci 2018 ; 36 : 1374-1375.
 
8) Matsumoto H, Terao Y, Furubayashi T, et al. Small saccades restrict visual scanning area in Parkinson's disease. Mov Disord 2011 ; 26 : 1619-1626.
PubMed
9) Rascol O, Sabatini U, Simonetta-Moreau M, et al. Square wave jerks in Parkinsonian syndromes. J Neurol Neurosurg Psychiatry 1991 ; 54 : 599-602.
PubMed
10) Anderson T, Luxob L, Quinn N, et al. Oculomotor function in multiple system atrophy : Clinical and laboratory features in 30 patients. Mov Disord 2008 ; 23 : 977-984.
 
11) Lee JY, Lee WW, Kim JS, et al. Perverted head-shaking nystagmus and positional downbeat nystagmus in patients with multiple system atrophy. Mov Disord 2009 ; 24 : 1290-1295.
PubMed
12) Otero-Millan J, Schneider R, Leigh RJ. et al. Saccades during attempted fixation in Parkinsonian Disorders and recessive ataxia : From microsaccades to square-wave jerks. PLOS one 2013 ; 8 : e58535, 1-9.
 
13) Troost BT, Daroff RB. The ocular motor defects in progressive supranuclear palsy. Ann Neurol 1977 ; 2 : 397-403.
PubMed
14) Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 ; 80 : 496-503.
PubMed
15) Anderson TJ, MacAskill MR. Eye movements in patients with neurodegenerative disorders. Nat Rev Neurol 2013 ; 9 : 74-85.
PubMed
P.36 掲載の参考文献
1) 大槻美佳. 言語機能の局在地図. 高次脳機能障害研究 2007 ; 27 : 231-243.
 
2) 大槻美佳. Anarthrieの症候学. 神経心理学 2005 ; 21 : 172-182.
 
3) Josephs KA, Duffy JR, Strand EA, et al. Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. Neurology 2013 ; 81 : 337-345.
PubMed
4) Takakura Y, Otsuki M, Sakai S, et al. Sub-classification of apraxia of speech in patients with cerebrovascular and neurodegenerative diseases. Brain and Cognition 2019 ; 130 : 1-10.
PubMed
5) Mesulam MM. Primary progressive aphasia : a language-based dementia. N Engl J Med 2003 ; 349 : 1535-1542.
PubMed
6) Gorno-Tempini ML, Hillis AE, Weinstraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011 ; 76 : 1006-1014.
 
7) Josephs KA, Duffy JR, Strand EA, et al. Characterizing a neurodegenerative syndrome : Primary progressive apraxia of speech. Brain 2012 ; 135 : 1522-1536.
PubMed
8) Soliveri P, Piacentini S, Girotti F. Limb apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology 2005 ; 64 : 448-453.
PubMed
9) Brion S, Jedynak P. Troubles du transfer interhemispherique. A propos de trois observations de tumeurs du corps calleux. Le sign de la main etrangere. Rev Neurol 1972 ; 126 : 257-266.
 
10) Bogen JE. The callosal syndrome. In Clinical neuropsychology (Heilman KM, Valenstein EV eds), Oxford University Press, New York, pp308-359, 1979
 
11) Feinberg TE, Schindler RJ, Flanagan NG, et al. Two alien hand syndromes. Neurology 1992 ; 42 : 19-24.
 
12) Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 ; 80 : 496-503.
PubMed
13) Hoglinger GU, Huppertz HJ, Wagenpfeil S, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord 2014 ; 29 : 479-487.
 
14) Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008 ; 71 : 670-676.
 
15) Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 1998 ; 51 : 1546-1554.
PubMed
16) The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 2014 ; 57 : 416-418.
 
17) Karageorgiou E, Miller BL. Frontotemporal lobar degeneration : a clinical approach. Semin Neurol 2014 ; 34 : 189-201.
PubMed
P.44 掲載の参考文献
1) Miki T, Yokota O, Ishizu H, et al. Behavioral variant of frontotemporal dementia : Fundamental clinical issues associated with prediction of pathological bases. Neuropathology 2016 ; 36 : 388-404.
PubMed
2) Cummings JL. Neuropsychiatric assessment of patients with dementia. The neuropsychiatry of Alzheimer's disease and related dementias. The first edition, Cummings JL edit. Martin Dunitz. pp23-56. CRC Press. 2002.
 
3) Nagao S, Yokota O, Ikeda C, et al. Argyrophilic grain disease as a neurodegenerative substrate in late-onset schizophrenia and delusional disorders. Eur Arch Psychiatry Clin Neurosci 2014 ; 264 : 317-331.
PubMed
4) Ballard C, Holmes C, McKeith I, et al. Psychiatric morbidity in dementia with Lewy bodies : a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry 1999 ; 156 : 1039-1045.
PubMed
5) Litvan I, Mega MS, Cummings JL, et al. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996 ; 47 : 1184-1189.
PubMed
6) Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001 ; 13 : 42-49.
PubMed
7) Litvan I, Cummings JL, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998 ; 65 : 717-721.
PubMed
8) Tatsumi S, Mimuro M, Iwasaki Y, et al. Argyrophilic grains are reliable disease-specific features of corticobasal degeneration. J Neuropathol Exp Neurol 2014 ; 73 : 30-38.
PubMed
9) Ikeda C, Yokota O, Nagao S, et al. The relationship between development of neuronal and astrocytic tau pathologies in subcortical nuclei and progression of argyrophilic grain disease. Brain Pathol 2016 ; 26 : 488-505.
PubMed
10) Yokota O, Miki T, Ikeda C, et al. Neuropathological comorbidity associated with argyrophilic grain disease. Neuropathology 2018 ; 38 : 82-97.
PubMed
11) Geda YE, Boeve BF, Negash S, et al. Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. J Neuropsychiatry Clin Neurosci 2007 ; 19 : 77-80.
 
12) Ikeda C, Yokota O, Nagao S, et al. Corticobasal degeneration initially developing motor versus non-motor symptoms : a comparative clinicopathological study. Psychogeriatrics 2014 ; 14 : 152-164.
PubMed
13) Brown RG, Lacomblez L, Landwehrmeyer BG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010 ; 133 : 2382-2393.
PubMed
14) Kao AW, Racine CA, Quitania LC, et al. Cognitive and neuropsychiatric profile of the synucleinopathies : Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimer Dis Assoc Disord 2009 ; 23 : 365-370.
PubMed
15) Almeida L, Ahmed B, Walz R, et al. Depressive symptoms are frequent in atypical parkinsonian disorders. Mov Disord Clin Pract 2017 ; 4 : 191-197.
PubMed
16) 博野信次, 森悦朗, 池尻義隆, 他. 日本語版Neuropsychiatric Inventory-痴呆の精神症状評価法の有用性の検討. 脳神経 1997 ; 49 : 266-271.
 
P.50 掲載の参考文献
1) Cochen De Cock V. Sleep abnormalities in multiplesystem atrophy. Curr Treat Options Neurol 2018 ; 20 : 16.
PubMed
2) Ghorayeb I, Bioulac B, Tison F. Sleep disorders in multiple system atrophy. J Neural Transm (Vienna) 2005 ; 112 : 1669-1675.
PubMed
3) Shimohata T, Nakayama H, Tomita M, et al. Daytime sleepiness in Japanese patients with multiple system atrophy : prevalence and determinants. BMC Neurol 2012 ; 12 : 130.
PubMed
4) Moreno-Lopez C, Santamaria J, Salamero M, et al. Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). Arch Neurol 2011 ; 68 : 223-230.
PubMed
5) Martinez-Rodriguez JE, Seppi K, Cardozo A, et al. Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy. Mov Disord 2007 ; 22 : 1822-1824.
PubMed
6) Benarroch EE, Schmeichel AM, Sandroni P, et al. Involvement of hypocretin neurons in multiple system atrophy. Acta Neuropathol 2007 ; 113 : 75-80.
PubMed
7) Mishima T, Kasanuki K, Koga S, et al. Reduced orexin immunoreactivity in Perry syndrome and multiple system atrophy. Parkinsonism Relat Disord 2017 ; 42 : 85-89.
PubMed
8) Guo XY, Cao B, Lei F, et al. Clinical and polysomnographic features of patients with multiple system atrophy in Southwest China. Sleep Breath 2013 ; 17 : 1301-1307.
PubMed
9) Ghorayeb I, Dupouy S, Tison F, et al. Restless legs syndrome in multiple system atrophy. J Neural Transm (Vienna) 2014 ; 121 : 1523-1527.
PubMed
10) Iranzo A, Santamaria J, Rye DB, et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 2005 ; 65 : 247-252.
PubMed
11) Wetter TC, Collado-Seidel V, Pollmacher T, et al. Sleep and periodic leg movement patterns in drugfree patients with Parkinson's disease and multiple system atrophy. Sleep 2000 ; 23 : 361-367.
PubMed
12) Benarroch EE. Brainstem respiratory control : substrates of respiratory failure of multiple system atrophy. Mov Disord 2007 ; 22 : 155-161.
PubMed
13) Silber M. Sleep Dysfunction in Parkinson's Plus Syndrome. In : Chokroverty S, Allen RP, Walters AS, et al., eds. Sleep and movement disorders, 2nd ed. New York : Oxford University Press, 2013 : 687-695.
 
14) Wenning GK, Tison F, Ben Shlomo Y, et al. Multiple system atrophy : a review of 203 pathologically proven cases. Mov Disord 1997 ; 12 : 133-147.
PubMed
15) 磯崎英治. 孤発性脊髄小脳変性症 : 多系統萎縮症における上気道閉塞. 神経進歩 2006 ; 50 : 409-419.
 
16) Shimohata T, Tomita M, Nakayama H, et al. Floppy epiglottis as a contraindication of CPAP in patients with multiple system atrophy. Neurology 2011 ; 76 : 1841-1842.
PubMed
17) 作田英樹, 鈴木圭輔, 宮本雅之, 他. 多系統萎縮症における喉咽頭所見と睡眠関連呼吸障害. 自律神経 2013 ; 50 : 48-52.
 
18) Deguchi K, Ikeda K, Goto R, et al. The close relationship between life-threatening breathing disorders and urine storage dysfunction in multiple system atrophy. J Neurol 2010 ; 257 : 1287-1292.
PubMed
19) 作田英樹, 宮本雅之, 鈴木圭輔, 他. 病初期に声帯外転麻痺, floppy arytenoidを呈した多系統萎縮症の肥満女性例. 臨床神経 2012 ; 52 : 421-424.
 
20) Uzawa A, Sakakibara R, Tamura N, et al. Laryngeal abductor paralysis can be a solitary manifestation of multiple system atrophy. J Neurol Neurosurg Psychiatry 2005 ; 76 : 1739-1741.
PubMed
21) Ohshima Y, Nakayama H, Matsuyama N, et al. Natural course and potential prognostic factors for sleep-disordered breathing in multiple system atrophy. Sleep Med 2017 ; 34 : 13-17.
PubMed
22) Iranzo A, Santamaria J, Tolosa E, et al. Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 2004 ; 63 : 930-932.
PubMed
23) Giannini G, Calandra-Buonaura G, Mastrolilli F, et al. Early stridor onset and stridor treatment predict survival in 136 patients with MSA. Neurology 2016 ; 87 : 1375-1383.
PubMed
24) Shimohata T, Aizawa N, Nakayama H, et al. Mechanisms and prevention of sudden death in multiple system atrophy. Parkinsonism Relat Disord 2016 ; 30 : 1-6.
PubMed
25) Hogl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration-an update. Nat Rev Neurol 2018 ; 14 : 40-55.
PubMed
26) Nomura T, Inoue Y, Hogl B, et al. Comparison of the clinical features of rapid eye movement sleep behavior disorder in patients with Parkinson's disease and multiple system atrophy. Psychiatry Clin Neurosci 2011 ; 65 : 264-271.
PubMed
27) Walsh CM, Ruoff L, Walker K, et al. Sleepless night and day, the plight of progressive supranuclear palsy. Sleep 2017 ; 40.
PubMed
28) Gama RL, Tavora DG, Bomfim RC, et al. Sleep disturbances and brain MRI morphometry in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy-a comparative study. Parkinsonism Relat Disord 2010 ; 16 : 275-279.
PubMed
29) Matsubara T, Suzuki K, Fujita H, et al. Restless legs syndrome, leg motor restlessness and their variants in patients with Parkinson's disease and related disorders. J Neurol Sci 2018 ; 393 : 51-57.
PubMed
30) Abbott SM, Videnovic A. Sleep disorders in atypical parkinsonism. Mov Disord Clin Pract 2014 ; 1 : 89-96.
PubMed
31) Cooper AD, Josephs KA. Photophobia, visual hallucinations, and REM sleep behavior disorder in progressive supranuclear palsy and corticobasal degeneration : a prospective study. Parkinsonism Relat Disord 2009 ; 15 : 59-61.
PubMed
32) Roche S, Jacquesson JM, Destee A, et al. Sleep and vigilance in corticobasal degeneration : a descriptive study. Neurophysiol Clin 2007 ; 37 : 261-264.
 
33) Mollenhauer B, Zimmermann J, Sixel-Doring F, et al. Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 2016 ; 87 : 168-177.
PubMed
P.56 掲載の参考文献
1) Higo R, Nito T, Tayama N. Swallowing function in patients with multiple-system atrophy with a clinical predominance of cerebellar symptoms (MSA-C). Eur Arch Otorhinolaryngol 2005 ; 262 : 646-650.
PubMed
2) Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008 ; 71 : 670-676.
 
3) Lee HH, Seo HG, Kim KD, et al. Characteristics of early oropharyngeal dysphagia in patients with multiple system atrophy. Neurodegener Dis 2018 ; 18 : 84-90.
PubMed
4) Alfonsi E, Versino M, Merlo IM, et al. Electrophysiologic patterns of oral-pharyngeal swallowing in parkinsonian syndromes. Neurology 2007 ; 68 : 583-589.
PubMed
5) Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival : a clinicopathological study. J Neurol Neurosurg Psychiatry 1996 ; 60 : 615-620.
PubMed
6) Litvan I, Sastry N, Sonies BC. Characterizing swallowing abnormalities in progressive supranuclear palsy. Neurology 1997 ; 48 : 1654-1662.
PubMed
7) Tomita S, Oeda T, Umemura A, et al. Impact of aspiration pneumonia on the clinical course of progressive supranuclear palsy : A retrospective cohort study. PLoS One 2015 ; 10 : e0135823.
PubMed
8) Johnston BT, Castell JA, Stumacher S, et al. Comparison of swallowing function in Parkinson's disease and progressive supranuclear palsy. Mov Disord 1997 ; 12 : 322-327.
PubMed
9) 市原典子, 市原新一郎, 藤井正吾, 他. Videofluorographyをもちいたパーキンソン病, 進行性核上性麻痺の嚥下障害の検討. 臨床神経 2000 ; 40 : 1076-1082.
 
10) Wakasugi Y, Yamamoto T, Oda C, et al. Effect of an impaired oral stage on swallowing in patients with Parkinson's disease. J Oral Rehabil 2017 ; 44 : 756-762.
PubMed
11) Warnecke T, Oelenberg S, Teismann I, et al. Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy. Mov Disord 2010 ; 25 : 1239-1245.
PubMed
12) Grunho M, Sonies B, Frattali CM, et al. Swallowing disturbances in the corticobasal syndrome. Parkinsonism Relat Disord 2015 ; 21 : 1342-1348.
PubMed
13) Londos E, Hanxsson O, Alm Hirsch I, et al. Dysphagia in Lewy body dementia-a clinical observational study of swallowing function by videofluoroscopic examination. BMC Neurol 2013 ; 13 : 140.
PubMed
14) 梅本丈二, 坪井義夫, 古谷博和, 他. レビー小体型認知症患者の摂食・嚥下障害-改訂版 長谷川式簡易知能評価スケールとの関連について-. 老年歯学 2011 ; 26 : 339-345.
 
15) Yamamoto T, Kobayashi Y, Murata M. Risk of pneumonia onset and discontinuation of oral intake following videofluorography in patients with Lewy body disease. Parkinsonism Relat Disord 2010 ; 16 : 503-506.
PubMed
16) Varanese S, Di Ruscio P, Ben M'Barek L, et al. Responsiveness of dysphagia to acute L-Dopa challenge in progressive supranuclear palsy. J Neurol 2014 ; 261 : 441-442.
PubMed
17) Logemann JA, Gensler G, Robbins J, et al. A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson's disease. J Speech Lang Hear Res 2008 ; 51 : 173-183.
PubMed
18) Warnecke T, Oelenberg S, Teismann I, et al. Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy. Mov Disord 2010 ; 25 : 1239-1245.
PubMed
P.60 掲載の参考文献
1) 日本神経学会. 筋萎縮性側索硬化症ガイドライン. 2013 : 162-177.
 
2) 浅川孝司, 吉野英, 西澤正豊, 他. 多系統萎縮症における治療介入に関する検討-筋萎縮性側索硬化症との比較-. 神経内科 2016 ; 84 : 600-605.
 
3) 成田有吾. 人工呼吸管理下にある筋萎縮性側索硬化症患者のコミュニケーション支援 現状と将来展望. 神経内科 2017 ; 87 : 539-544.
 
4) Hatakeyama M, Sato T, Takahashi T, et al. Predictors of cognitive impairment in multiple system atrophy. J Neurol Sci 2018 ; 388 : 128-132.
PubMed
5) 林健太郎, 望月葉子, 中山優季, 他. 侵襲的陽圧補助換気導入後の筋萎縮性側索硬化症における意思伝達能力障害-Stage分類の提唱と予後予測因子の検討-. 臨床神経 2013 ; 53 : 98-103.
 
6) 井村保. 神経筋疾患患者に対するコミュニケーション機器導入支援ガイドブック～ALを中心とした支援にかかわる医療職のための基礎知識～. 2016.
 
P.65 掲載の参考文献
1) Respondek G, Kurz C, Arzberger T, et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 2017 ; 32 : 995-1005.
PubMed
2) Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework : Toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018 ; 14 : 535-562.
 
3) Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease : a systematic review and meta-analysis. Lancet Neurol 2016 ; 15 : 673-684.
PubMed
4) Toledo JB, Brettschneider J, Grossman M, et al. CSF biomarkers cutoffs : the importance of coincident neuropathological diseases. Acta Neuropathol 2012 ; 124 : 23-35.
PubMed
5) Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012 ; 69 : 1445-1452.
PubMed
6) Hansson O, Janelidze S, Hall S, et al. Blood-based NfL : A biomarker for differential diagnosis of parkinsonian disorder. Neurology 2017 ; 88 : 930-937.
PubMed
7) Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2015 ; 86 : 1240-1247.
PubMed
8) Wagshal D, Sankaranarayanan S, Guss V, et al. Divergent CSF tau alterations in two common tauopathies : Alzheimer's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2015 ; 86 : 244-250.
PubMed
9) Chen Z, Mengel D, Keshavan A, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. Alzheimers Dement 2018 [Epub ahead of print]
 
10) Sato C, Barthelemy NR, Mawuenyega KG, et al. Tau kinetics in neurons and the human central nervous system. Neuron 2018 ; 98 : 861-864.
PubMed
11) Cicognola C, Brinkmalm G, Wahlgren J, et al. Novel tau fragments in cerebrospinal fluid : relation to tangle pathology and cognitive decline in Alzheimer's disease. Acta Neuropathol 2018 [Epub ahead of print]
 
12) Kasuga K, Nishizawa M, Ikeuchi T. Alpha-synuclein as CSF and blood biomarker of dementia with Lewy bodies. Int J Alzheimers Dis 2012 ; 2012 : 437025.
PubMed
13) Laurens B, Constantinescu R, Freeman R, et al. Fluid biomarkers in multiple system atrophy : A review of the MSA Biomarker Initiative. Neurobiol Dis 2015 ; 80 : 29-41.
PubMed
14) Magdalinou N, Lees AJ, Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions : an update and future directions. J Neurol Neurosurg Psychiatry 2014 ; 85 : 1065-1075.
PubMed
15) Olsson B, Portelius E, Cullen NC, et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol 2018 [Epub ahead of print]
 
16) Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018 ; 14 : 577-589.
PubMed
17) Boyle PA, Yu L, Wilson RS, et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol 2018 ; 83 : 74-83.
PubMed
18) Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci 2013 ; 5 : 17.
PubMed
19) Dugger BN, Adler CH, Shill HA, et al. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord 2014 ; 20 : 525-529.
PubMed
20) Dugger BN, Hentz JG, Adler CH, et al. Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol 2014 ; 73 : 244-252.
 
21) Ling H, Kovacs GG, Vonsattel JP, et al. Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain 2016 ; 139 : 3237-3252.
PubMed
P.71 掲載の参考文献
1) Meyer PT, Hellwig S. Update on SPECT and PET in parkinsonism-part 1 : imaging for differential diagnosis. Curr Opin Neurol 2014 ; 27 : 390-397.
PubMed
2) Tripathi M, Dhawan V, Peng S, et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology 2013 ; 55 : 483-492.
PubMed
3) Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994 ; 14 : 783-801.
PubMed
4) Huang C, Mattis P, Tang C, et al. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007 ; 34 : 714-723.
PubMed
5) Meles SK, Teune LK, de Jong BM, et al. Metabolic imaging in Parkinson disease. J Nucl Med 2017 ; 58 : 23-28.
PubMed
6) Wang J, Ma Y, Huang Z, et al. Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease. J Neurol 2010 ; 257 : 72-78.
PubMed
7) Saari L, Kivinen K, Gardberg M, et al. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology 2017 ; 88 : 1461-1467.
 
8) Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009 ; 73 : 273-278.
PubMed
9) Shinotoh H, Namba H, Yamaguchi M, et al. Positron emission tomography measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 1999 ; 46 : 62-69.
PubMed
10) Hirano S, Shinotoh H, Shimada H, et al. Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain 2010 ; 133 : 2058-2068.
PubMed
11) Gilman S, Koeppe RA, Nan B, et al. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 2010 ; 74 : 1416e23.
PubMed
12) Bohnen NI, Muller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009 ; 73 : 1670-1676.
PubMed
13) Shimada H, Hirano S, Sinotoh H, et al. Dementia with Lewy bodies can be well-differentiated from Alzheimer's disease by measurement of brain acetylcholinesterase activity-a [11C] MP4A PET study. Int J Geriatr Psychiatry 2015 ; 30 : 1105-1113.
PubMed
14) Kikuchi A, Takeda A, Okamura N, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2- [2- (2-dimethylaminothiazol-5-yl) ethenyl] -6- [2- (fluoro) ethoxy] benzoxazole positron emission tomography in multiple system atrophy. Brain 2010 ; 133 : 1772-1778.
PubMed
15) Verdurand M, Levigoureux E, Lancelot S, et al. Amyloid-beta radiotracer [18F] BF-227 does not bind to cytoplasmic glial inclusions of postmortem multiple system atrophy brain tissue. Contrast Media Mol Imaging 2018 ; 2018 : 9165458.
 
16) Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013 ; 79 : 1094-1108.
 
17) Endo H, Shimada H, Sahara N, et al. In-vivo binding of a tau imaging probe, [11C] PBB3, in patients with progressive supranuclear palsy. Mov Disord 2019. doi : 10.1002/mds.27643. [Epub ahead of print]
 
18) Ikeda A, Shimada H, Nishioka K, et al. Clinical heterogeneity of frontotemporal dementia and parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features. Mov Disord 2019. doi : 10.1002/mds.27623. [Epub ahead of print]
 
19) Shinotoh H, Shimada H, Kokubo Y, et al. Tau imaging detects distinctive distribution of tau pathology in ALS/PDC on the Kii Peninsula. Neurology 2019 ; 92 : e136-e147.
PubMed
P.79 掲載の参考文献
1) 日本神経学会 (監). パーキンソン病診療ガイドライン 2018. 2018, 87-89.
 
2) 日本理学療法士協会 (監) : 日本理学療法診療ガイドライン 第一版. 2011, 218-234.
 
3) White DK, Wagenaar RC, Ellis TD, et al. Changes in waking activity and endurance following rehabilitation for people with Parkinson disease. Arch Phys Med Rehabil 2009 ; 90 : 43-50.
 
4) Marchese R, Diverio M, Zucchi F, et al. The role of sensory cues in the rehabilitation of parkinsonian patients. a comparison of two physical therapy protocols. Mov Disord 2000 ; 15 : 879-883.
PubMed
5) Corcos DM, Chen C-M, Quinn NP, et al. Relationship of strength to rate of force in Parkinson's disease. Ann Neurol 1996 ; 39 : 79-88.
PubMed
6) 望月久. 協調性障害の理学療法. 理学療法のあゆみ 2007 ; 18 : 8-13.
 
7) Yogev G, Plotnik M, Peretz C, et al. Gait asymmetry in patients with Parkinson's disease and elderly fallers : when does the bilateral coordination of gait require attention? Exp Brain Res 2007 ; 177 : 336-346.
PubMed
8) Spaulding SJ, Barber B, Colby M, et al. Cueing and gait improvement among people with Parkinson's disease : A meta-analysis. Arch Phys Med Rehabil 2013 ; 94 : 562-570.
PubMed
9) Miyai I, Fujimoto Y, Ueda Y, et al. Treadmill training with body weight support : its effect on Parkinson's disease. Arch Phys Med Rehabil 2000 ; 81 : 849-852.
PubMed
10) Clerici I, Ferrazzoli D, Maestri R, et al. Supported treadmill ambulation training after spinal cord injury : A pilot study. Arch Phys Med Rehabil 2001 ; 32 : 825-831.
 
11) 濱崎寛臣, 大久保智明, 野尻晋一, 他. パーキンソン病の環境整備. 理学療法 2008 ; 25 : 1544-1550.
 

II 各論

P.87 掲載の参考文献
1) Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med 2015 ; 372 : 249-263.
PubMed
2) Watanabe H, Riku Y, Hara K, et al. Clinical and imaging features of multiple system atrophy : Challenges for an early and clinically definitive diagnosis. J Mov Disord 2018 ; 11 : 107-120.
PubMed
3) 高橋昭. 進行性自律神経不全症を伴う多系統萎縮症-その疾患概念に至る歴史的変遷-. 東女医大 1993 ; 63 : 108-115.
 
4) Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989 ; 94 : 79-100.
PubMed
5) Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 1998 ; 8 : 359-362.
PubMed
6) Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008 ; 71 : 670-676.
 
7) Osaki Y, Ben-Shlomo Y, Lees AJ, et al. A validation exercise on the new consensus criteria for multiple system atrophy. Mov Disord 2009 ; 24 : 2272-2276.
PubMed
8) Koga S, Aoki N, Uitti RJ, et al. When DLB, PD, and PSP masquerade as MSA An autopsy study of 134 patients. Neurology 2015 ; 85 : 404-412.
PubMed
9) Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy : an analysis of 230 Japanese patients. Brain 2002 ; 125 : 1070-1083.
PubMed
10) Shimohata T, Ozawa T, Nakayama H, et al. Frequency of nocturnal sudden death in patients with multiple system atrophy. J Neurol 2008 ; 255 : 1483-1485.
PubMed
11) Batla A, De Pablo-Fernandez E, Erro R, et al. Young-onset multiple system atrophy : Clinical and pathological features. Mov Disord 2018 ; 33 : 1099-1107.
PubMed
12) Sakushima K, Nishimoto N, Nojima M, et al. Epidemiology of multiple system atrophy in Hokkaido, the northernmost island of Japan. Cerebellum 2015 ; 14 : 682-687.
PubMed
13) Petrovic IN, Ling H, Asi Y, et al. Multiple system atrophy-parkinsonism with slow progression and prolonged survival : a diagnostic catch. Mov Disord 2012 ; 27 : 1186-1190.
PubMed
14) Aoki N, Boyer PJ, Lund C, et al. Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration : frontotemporal lobar degeneration associated with alpha-synuclein. Acta Neuropathologica 2015 ; 130 : 93-105.
PubMed
15) Stankovic I, Krismer F, Jesic A, et al. Cognitive impairment in multiple system atrophy : a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord 2014 ; 29 : 857-867.
 
16) Riku Y, Watanabe H, Mimuro M, et al. Non-motor multiple system atrophy associated with sudden death : pathological observations of autonomic nuclei. J Neurol 2017 ; 264 : 2249-2257.
PubMed
P.93 掲載の参考文献
1) Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969 ; 32 : 28-34.
 
2) Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989 ; 94 : 79-100.
PubMed
3) Wakabayashi K, Yoshimoto M, Tsuji S, et al. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998 ; 249 : 180-182.
PubMed
4) Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008 ; 71 : 670-676.
 
5) Wenning GK, Colosimo C, Geser F, et al. Multiple system atrophy. Lancet Neurol 2004 ; 3 : 93-103.
PubMed
6) Kraft E, Schwarz J, Trenkwalder C, et al. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences : a specific marker of multiple system atrophy? Arch Neurol 1999 ; 56 : 225-228.
PubMed
7) Watanabe H, Ito M, Fukatsu H, et al. Putaminal magnetic resonance imaging features at various magnetic field strengths in multiple system atrophy. Mov Disord 2010 ; 25 : 1916-1923.
PubMed
8) Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy : an analysis of 230 Japanese patients. Brain 2002 ; 125 : 1070-1083.
PubMed
9) Lin IS, Wu RM, Lee-Chen GJ, et al. The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment. Parkinsonism Relat Disord 2007 ; 13 : 246-249.
PubMed
10) Lee YC, Liu CS, Wu HM, et al. The 'hot cross bun' sign in the patients with spinocerebellar ataxia. Eur J Neurol 2009 ; 16 : 513-516.
 
11) Nagayama H, Ueda M, Yamazaki M, et al. Abnormal cardiac [ (123) I] -meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord 2010 ; 25 : 1744-1747.
PubMed
12) Brenneis C, Seppi K, Schocke MF, et al. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Mov Disord 2003 ; 18 : 1132-1138.
PubMed
13) Brenneis C, Boesch SM, Egger KE, et al. Cortical atrophy in the cerebellar variant of multiple system atrophy : a voxel-based morphometry study. Mov Disord 2006 ; 21 : 159-165.
PubMed
14) Ito M, Watanabe H, Kawai Y, et al. Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. J Neurol Neurosurg Psychiatry 2007 ; 78 : 722-728.
PubMed
15) Ji L, Zhu D, Xiao C, et al. Tract based spatial statistics in multiple system atrophy : a comparison between clinical subtypes. Parkinsonism Relat Disord 2014 ; 20 : 1050-1055.
PubMed
16) Hara K, Watanabe H, Bagarinao E, et al. Corpus callosal involvement is correlated with cognitive impairment in multiple system atrophy. J Neurol 2018 ; 265 : 2079-2087.
PubMed
17) Zanigni S, Evangelisti S, Testa C, et al. White matter and cortical changes in atypical parkinsonisms : A multimodal quantitative MR study. Parkinsonism Relat Disord 2017 ; 39 : 44-51.
PubMed
18) Ito K, Ohtsuka C, Yoshioka K, et al. Differential diagnosis of parkinsonism by a combined use of diffusion kurtosis imaging and quantitative susceptibility mapping. Neuroradiology 2017 ; 59 : 759-769.
PubMed
19) Wang N, Edmiston EK, Luo X, et al. Comparing abnormalities of amplitude of low-frequency fluctuations in multiple system atrophy and idiopathic Parkinson's disease measured with resting-state fMRI. Psychiatry Res Neuroimaging 2017 ; 269 : 73-81.
PubMed
20) Yao Q, Zhu D, Li F, et al. Altered functional and causal connectivity of cerebello-cortical circuits between multiple system atrophy (parkinsonian type) and Parkinson's disease. Front Aging Neurosci 2017 ; 9 : 266. eCollection 2017.
 
P.99 掲載の参考文献
1) Holton JL, Lees AJ, Revez T. Multiple system atrophy. NEURODEGENERATION the molecular pathology of dementia and movement disorders, Second edition, Dickson DW and Weller RO, Wiley-Blackwell, 2011, 242-252.
 
2) Dickson DW. Parkinson's disease and parkinsonism : neuropathology. Cold Spring Harb Perspect Med 2012 : 2 ; pii : a009258.
 
3) Trojanowski JQ, Revesz T. Neuropathology Working Group on MSA. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 2007 ; 33 : 615-620.
 
4) 水野俊雄. 神経病理形態学 ミクロの世界へのガイドブック. 新興医学出版社, 2003, 178-179, 241-243.
 
5) Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy : clinicopathological correlations. Brain 2004 ; 127 : 2657-2671.
PubMed
6) Coon EA, Cutsforth-Gregory JK, Benarroch EE. Neuropathology of autonomic dysfunction in synucleinopathies. Mov Disord 2018 ; 33 : 349-358.
PubMed
7) Nakamura K, Mori F, Kon T, et al. Filamentous aggregations of phosphorylated α-synuclein in Schwann cells (Schwann cell cytoplasmic inclusions) in multiple system atrophy. Acta Neuropathol Commun 2015 ; 3 : 29.
 
8) Benarroch EE, Smithson IL, Low PA, et al. Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure. Ann Neurol 1998 ; 43 : 156-163.
PubMed
9) Benarroch EE, Schmeichel AM, Low PA, et al. Involvement of medullary serotonergic groups in multiple system atrophy. Ann Neurol 2004 ; 55 : 418-422.
PubMed
10) Benarroch EE, Schmeichel AM, Low PA, et al. Depletion of putative chemosensitive respiratory neurons in the ventral medullary surface in multiple system atrophy. Brain 2007 ; 130 : 469-475.
PubMed
11) Tada M, Kakita A, Toyoshima Y, et al. Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death. Brain 2009 ; 132 : 1810-1819.
PubMed
12) Stankovic I, Krismer F, Jesic A, et al. Cognitive impairment in multiple system atrophy : a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord 2014 ; 29 : 857-867.
 
13) Aoki N, Boyer PJ, Lund C, et al. Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration : frontotemporal lobar degeneration associated with α-synuclein. Acta Neuropathol 2015 ; 130 : 93-105.
 
14) Piao YS, Hayashi S, Hasegawa M, et al. Co-localization of alpha-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. Acta Neuropathol 2001 ; 101 : 285-293.
 
15) Peng C, Gathagan RJ, Covell DJ, et al. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. Nature 2018 ; 557 : 558-563.
 
P.104 掲載の参考文献
1) Wenning GK, et al. The natural history of multiple system atrophy : a prospective European cohort study. Lancet Neurol 2013 ; 12 : 264-274.
PubMed
2) Elgebaly A, et al. Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension. Clin Aut Res 2016 ; 26 : 171-180.
 
3) Isaacson S, Shill HA, Vernino S, et al. Safety and durability of effect with long-term, open-label droxidopa treatment in patients with symptomatic neurogenic orthostatic hypotension (NOH303). J Park Dis 2016 ; 6 : 751-759.
 
4) Shimohata T, et al. Mechanisms and prevention of sudden death in multiple system atrophy. Park Relat Disord ; 2016. doi : 10.1016/j.parkreldis. 2016. 04. 011
 
5) Friess E, et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Park Relat Disord 2006 ; 12 : 432-437.
 
6) The Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 2013 ; 369 : 233-244.
PubMed
7) Mitsui J, et al. Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations. Cerebellum 2017 ; 16 : 664-672.
 
8) Zhao Q, et al. Association of the COQ2 V393A variant with risk of multiple system atrophy in East Asians : a case-control study and meta-analysis of the literature. Neurol Sci 2015 ; 37 : 423-430.
PubMed
9) Kasai T, et al. Serum levels of coenzyme Q10 in patients with multiple system atrophy. PLoS One 2016 ; 11 : e0147574.
PubMed
10) Mitsui J, Matsukawa T, Yasuda T, et al. Plasma coenzyme Q10 levels in patients with multiple system atrophy. JAMA Neurol 2016 ; 73 : 977-980.
PubMed
11) Du J, et al. Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy. Parkinsonism Relat Disord ; 2018. doi : 10.1016/j.parkreldis. 2018. 07. 017
 
12) Barca E, et al. Decreased coenzyme Q10 levels in multiple system atrophy cerebellum. J Neuropathol Exp Neurol 2016 ; 75 : 663-672.
PubMed
13) Schottlaender LV, et al. Coenzyme Q10 levels are decreased in the cerebellum of multiple-system atrophy patients. PLoS One 2016 ; 11, e0149557.
PubMed
14) Compta Y, et al. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. Parkinsonism Relat Disord 2018 ; 46 : 16-23.
PubMed
15) Krismer F, et al. Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. Mov Disord 2016 ; 31 : 1577-1581.
PubMed
P.113 掲載の参考文献
1) Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964 ; 10 : 333-359.
PubMed
2) Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : report of the NINDS-SPSP international workshop. Neurology 1996 ; 47 : 1-9.
 
3) Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy : Richardson's syndrome and PSP-parkinsonism. Brain 2005 ; 128 : 1247-1258.
PubMed
4) Williams DR, Holton JL, Strand K, et al. Pure akinesia with gait freezing : a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007 ; 22 : 2235-2241.
PubMed
5) Respondek G, Kurz C, Arzberger T, et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 2017 ; 32 : 995-1005.
PubMed
6) Hoglinger GU, Respondek G, Stamelou M, et al. Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy : The movement disorder society criteria. Mov Disord 2017 ; 32 : 853-864.
 
7) Boxer AL, Yu JT, Golbe LI, et al. Advances in progressive supranuclear palsy : new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 2017 ; 16 : 552-556.
PubMed
8) Ali F, Martin PR, Botha H, et al. Sensitivity and specificity of dignostic criteria for progressive supranuclear palsy. Mov Disord 2019 [Epub ahead of print]
 
9) 今井寿正, 楢林博太郎. アキネジア-純粋アキネジアの2症例を中心として. 神経研究の進歩 1974 ; 18 : 787-794.
 
10) Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy : a retrospective multicenter study of 100 definite cases. Mov Disord 2014 ; 29 : 1758-1766.
PubMed
11) Donker Kaat L, Boon AJ, Kamphorst W, et al. Frontal presentation in progressive supranuclear palsy. Neurology 2007 ; 69 : 723-729.
PubMed
12) Josephs KA, Duffy JR, Strand EA, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006 ; 12 : 1385-1398.
 
13) Tsuboi Y, Josephs KA, Boeve BF, et al. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord 2005 ; 20 : 982-988.
PubMed
14) Shimohata T, Kanazawa M, Yoshida M, et al. Clinical and imaging findings of progressive supranuclear palsy with predominant cerebellar ataxia. Mov Disord 2016 ; 31 : 760-762.
PubMed
15) Nagao S, Yokota O, Nanba R, et al. Progressive supranuclear palsy presenting as primary lateral sclerosis but lacking parkinsonism, gaze palsy, aphasia, or dementia. J Neurol Sci 2012 ; 323 : 147-153.
PubMed
16) Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord 2010 ; 25 : 357-362.
PubMed
17) Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 ; 80 : 496-503.
PubMed
P.118 掲載の参考文献
1) Hoglinger GU, Respondek G, Stamelou M, et al, Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy : The movement disorder society criteria. Mov Disord 2017 ; 32 : 853-864.
 
2) Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci 2003 ; 210 : 57-60.
PubMed
3) Oba H, Yagishita A, Terada H, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005 ; 64 : 2050-2055.
PubMed
4) Broski SM, Hunt CH, Johnson GB, et al. Structural and functional imaging in parkinsonian syndromes. Radiographics 2014 ; 34 : 1273-1292.
PubMed
5) Paviour DC, Price SL, Stevens JM, et al. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 2005 ; 64 : 675-679.
PubMed
6) Santos-Santos MA, Mandelli ML, Binney RJ, et al. Features of patients with nonfluent/agrammatic primary progressive aphasia with underlying progressive supranuclear palsy pathology or corticobasal degeneration. JAMA Neurol 2016 ; 73 : 733-742.
PubMed
7) Sakurai K, Tokumaru AM, Shimoji K, et al. Beyond the midbrain atrophy : wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclear palsy. Neuroradiology 2017 ; 59 : 431-443.
PubMed
8) Shimohata T, Kanazawa M, Yoshida M, et al. Clinical and imaging findings of progressive supranuclear palsy with predominant cerebellar ataxia. Mov Disord 2016 ; 31 : 760-762.
PubMed
9) Sakurai K, Imabayashi E, Tokumaru AM, et al. Volume of interest analysis of spatially normalized PRESTO imaging to differentiate between Parkinson disease and atypical parkinsonian syndrome. Magn Reson Med Sci 2017 ; 16 : 16-22.
PubMed
10) Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008 ; 246 : 214-221.
PubMed
11) Quattrone A, Morelli M, Nigro S, et al. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease. Parkinsonism Relat Disord 2018 ; 54 : 3-8.
 
12) Sakurai K, Imabayashi E, Tokumaru AM, et al. The feasibility of white matter volume reduction analysis using SPM8 plus DARTEL for the diagnosis of patients with clinically diagnosed corticobasal syndrome and Richardson's syndrome. Neuroimage Clin 2014 ; 7 : 605-610.
PubMed
13) Shi HC, Zhong JG, Pan PL, et al. Gray matter atrophy in progressive supranuclear palsy : meta-analysis of voxel-based morphometry studies. Neurol Sci 2013 ; 34 : 1049-1055.
PubMed
14) Yang J, Shao N, Li J, et al. Voxelwise meta-analysis of white matter abnormalities in progressive supranuclear palsy. Neurol Sci 2014 ; 35 : 7-14.
PubMed
15) Agosta F, Kostic VS, Galantucci S, et al. The in vivo distribution of brain tissue loss in Richardson's syndrome and PSP-parkinsonism : a VBM-DARTEL study. Eur J Neurosci 2010 ; 32 : 640-647.
PubMed
16) Hong JY, Yun HJ, Sunwoo MK, et al. Comparison of regional brain atrophy and cognitive impairment between pure akinesia with gait freezing and Richardson's syndrome. Front Aging Neurosci 2015 ; 7 : 180.
PubMed
17) Santos-Santos MA, Mandelli ML, Binney RJ, et al. Features of patients with nonfluent/agrammatic primary progressive aphasia with underlying progressive supranuclear palsy pathology or corticobasal degeneration. JAMA Neurol 2016 ; 73 : 733-742.
PubMed
18) Tripathi M, Dhawan V, Peng S, et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology 2013 ; 55 : 483-492.
PubMed
19) Kahraman D, Eggers C, Schicha H, et al. Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease. J Neurol 2012 ; 259 : 251-260.
PubMed
20) Pirker W, Asenbaum S, Bencsits G, et al. [123I] beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000 ; 15 : 1158-1167.
PubMed
21) Lin WY, Lin KJ, Weng YH, et al. Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy. Nucl Med Commun 2010 ; 31 : 974-980.
PubMed
22) Han S, Oh M, Oh JS, et al. Subregional pattern of striatal dopamine transporter loss on 18F FP-CIT positron emission tomography in patients with pure akinesia with gait freezing. JAMA Neurol 2016 ; 73 : 1477-1484.
PubMed
P.126 掲載の参考文献
1) Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar plasy, nuchal dystonia and dementia. Arch Neurol 1964 ; 10 : 333-358.
 
2) Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. Jf Neuropathol Exp Neurol 1996 ; 55 : 97-105.
 
3) Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994 ; 44 : 2015-2019.
PubMed
4) Komori T, Arai N, Oda M, et al. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 1998 ; 96 : 401-408.
 
5) Iwasaki Y, Yoshida M, Hattori M, et al. Distribution of tuft-shaped astrocytes in the cerebral cortex in progressive supranuclear palsy. Acta Neuropathol 2004 ; 108 : 399-405.
PubMed
6) Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy : a retrospective multicenter study of 100 definite cases. Mov Disord 2014 ; 29 (14) : 1758-1766.
PubMed
7) Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy : the Movement Disorder Society criteria. Mov Disord 2017 ; 32 (6) : 853-864.
PubMed
8) Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy : Richardson's syndrome and PSP-parkinsonism. Brain 2005 ; 128 : 1247-1258.
PubMed
9) 本間義章, 高橋均, 武田茂樹, 他. "L-dopa無効の純粋アキネジア" を呈した進行性核上性麻痺の1剖検例. Brain Nerve 1987 ; 39 : 183-187.
 
10) Williams DR, Holton JL, Strand K, et al. Pure akinesia with gait freezing : a third clinical phenotype of progressive supranuclear palsy. Mov Disord. 2007 ; 22 : 2235-2241.
PubMed
11) Ling H, de Silva R, Massey LA, et al. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome : a cortical variant. Neuropathol Appl Neurobiol 2014 ; 40 : 149-163.
PubMed
12) Mochizuki A, Ueda Y, Komatsuzaki Y, et al. Progressive supranuclear palsy presenting with primary progressive aphasia-clinicopathological report of an autopsy case. Acta Neuropathol 2003 ; 105 : 610-614.
PubMed
13) Kanazawa M, Shimohata T, Toyoshima Y, et al. Cerebellar involvement in progressive supranuclear palsy : a clinicopathological study. Mov Disord 2009 ; 24 : 1312-1318.
PubMed
14) Iwasaki Y, Mori K, Ito M, et al. An autopsied case of progressive supranuclear palsy presenting with cerebellar ataxia and severe cerebellar involvement. Neuropathology 2013 ; 33 : 561-567.
PubMed
15) Yoshida M. Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 2014 ; 34, 555-570.
PubMed
P.131 掲載の参考文献
1) 進行性核上性麻痺. 診断とケアマニュアル ver. 4, 2017, pp 12-30.
 
2) Tolosa E, Litvan I, Hoglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 2014 ; 29 : 470-478.
PubMed
3) Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy : a randomized, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014 ; 13 : 676-685.
PubMed
4) Leclair-Visonneau L, Rounaud T, Debilly B, et al. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin Neurol Neurosurg 2016 ; 146 : 35-39.
 
5) Apetauerova D, Scala SA, Hamill RW, et al. CoQ10 in progressive supranuclear palsy : A randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm 2016 ; 3 : e266.
PubMed
6) Nuebling G, Hensler M, Paul S, et al. PROSPERA : a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J Neurol 2016 ; 263 : 1565-1574.
PubMed
7) Stamelou M, Schope J, Wagenpfeil S, et al. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. Mov Disord 2016 ; 31 : 742-747.
PubMed
8) West T, Hu Y, Verghese PB, et al. Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer's disease and other tauopathies. J Prev Alzehimers Dis 2017 ; 4 : 236-241.
 
9) Qureshi IA, Tirucherai G, Ahlijanian MK, et al. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimers Dement (NY) 2018 ; 4 : 746-755.
 
10) Novak P, Zilka N, Zilkova M, et al. AADvac1, an active immunotherapy for Alzheimer's disease and non Alzheimer tauopathies : an overview of preclinical and clinical development. J Prev Alzheimers Dis 2019 ; 61 : 63-69.
 
11) Panza F, Solfrizzi V, Seripa D, et al. Tau-based therapeutics for Alzheimer's disease : active and passive immunotherapy. Immunotherapy 2016 ; 8 : 1119-1134.
PubMed
P.138 掲載の参考文献
1) Rebeiz JJ, Kolodny EH, Richardson EP, Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968 ; 18 : 20-33.
PubMed
2) Cordato NJ, Halliday GM, McCann H, et al. Corticobasal syndrome with tau pathology. Mov Disord 2001 ; 16 : 656-667.
PubMed
3) Tolosa E, Litvan I, Hoglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 2014 ; 29 : 470-478.
PubMed
4) Hoglinger GU, Huppertz HJ, Wagenpfeil S, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord 2014 ; 29 : 479-487.
 
5) Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy : a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014 ; 13 : 676-685.
PubMed
6) ClinicalTrials. gov Identifier : NCT00532571.
 
7) Mathew R, Bak TH, Hodges JR. Diagnostic criteria for corticobasal syndrome : a comparative study. J Neurol Neurosurg Psychiatry 2012 ; 83 : 405-410.
PubMed
8) Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 ; 80 : 496-503.
PubMed
9) Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002 ; 61 : 935-946.
PubMed
10) Boeve BF, Maraganore DM, Parisi JE, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999 ; 53 : 795-800.
PubMed
11) Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003 ; 54 Suppl 5 : S15-19.
 
12) Lang AE, Riley DE, Bergeron C. Cortico-basal ganglionic degeneration. Neurodegenerative diseases 1994 ; Philadelphia : WB Saunders : 877-894.
 
13) Shelley BP, Hodges JR, Kipps CM, et al. Is the pathology of corticobasal syndrome predictable in life? Mov Disord 2009 ; 24 : 1593-1599.
PubMed
14) Rinne JO, Lee MS, Thompson PD, et al. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994 ; 117 : 1183-1196.
PubMed
15) Mathew R, Bak TH, Hodges JR. Diagnostic criteria for corticobasal syndrome : a comparative study. J Neurol Neurosurg Psychiatry 2012 ; 83 : 405-410.
PubMed
16) Ouchi H, Toyoshima Y, Tada M, et al. Pathology and sensitivity of current clinical criteria in corticobasal syndrome. Mov Disord 2014 ; 29 : 238-244.
PubMed
17) Alexander SK, Rittman T, Xuereb JH, et al. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 2014 ; 85 : 925-929.
PubMed
18) Day GS, Lim TS, Hassenstab J, et al. Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology 2017 ; 88 : 1273-1281.
PubMed
P.145 掲載の参考文献
1) Rebeiz JJ, Kolodny EH, Richardson Ep Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968 ; 18 : 20-33.
PubMed
2) Cordato NJ, Halliday GM, McCann H, et al. Corticobasal syndrome with tau pathology. Mov Disord 2001 ; 16 : 656-667.
PubMed
3) Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003 ; 54 (suup 5) : S15-19.
 
4) Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological reevaluation. Brain 2010 ; 133 : 2045-2057.
PubMed
5) Lee SE, Rabinovici GD, Mayo MC, et al. Seeley WW, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011 ; 70 : 327-340.
PubMed
6) Armstrong MJ, Litvan I, Lang AT, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 ; 80 : 496-503.
 
7) Mathew R, Bak TH, Hodges JR. Diagnostic criteria for corticobasal syndrome : a comparative study. J Neurol Neurosurg Psychiatry 2012 ; 83 : 405-410.
PubMed
8) 瀧川洋史. JALPAC (Japanese Longitudinal Biomarker Study in PSP and CBD). 神経治療 2017 ; 34 : 278-282.
Medical*Online
9) Koyama M, Yagishita A, Nakata Y, et al. Imaging of corticobasal degeneration syndrome. Neuroradiology 2007 ; 49 : 905-912.
PubMed
10) Tokumaru AM, Saito Y, Murayama S, et al. Imaging-pathologic correlation in corticobasal degeneration. AJNR 2009 ; 30 : 1884-1892.
PubMed
11) Tokumaru AM, O'uchi T, Kuru Y, et al. Coricobasal degeneration : MR with histopathologic comparison. AJNR 1996 ; 17 : 1849-1852.
PubMed
12) Sakurai K, Imabayashi E, Tokumaru AM, et al. The feasibility of white matter volume reduction analysis using plus DARTEL for the diagnosis of patients with clinically diagnosed corticobasal syndrome and Richardson's syndrome. Neuroimage Clin 2015 ; 17 : 605-610.
 
13) Yamauchi H, Fukuyama H, Nagahama Y, et al. Atrophy of the corpus callosum, cortical hypometabolism, and cognitive impairment in corticobasal degeneration. Arch Neurol 1998 ; 55 : 609-614.
PubMed
14) Kitagaki H, Hirono N, Ishii K, et al. Corticobasal degeneration : evaluation of cortical atrophy by means of hemispheric surface display generated with MR images. Radiology 2000 ; 216 : 31-38.
PubMed
15) Boxer Al, et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006 ; 63 : 81-86.
PubMed
16) Josephs KA, et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging 2008 ; 29 : 280-289.
PubMed
17) Erbeta A, et al. Diffusion tensor imaging shows different topographic involovement of the thalamus in progressive supranuclear palsy and corticobasal degeneration. AJNR 2009 ; 30 : 1482-1487.
 
18) Borroni B, Garibotto V, Agosti C, et al. White matter changes in corticobasal degeneration syndrome and correlation with limb apraxia. Arch Neurol 2008 ; 65 : 796-801.
PubMed
19) Boelmans K, Kaufmann J, Bodammer N, et al. Involvement of motor pathway in corticobasal syndrome detected by diffusion tensor tractography. Mov Disord 2009 ; 24 : 168-175.
PubMed
20) Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of the locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006 ; 17 : 1215-1218.
PubMed
21) Sasaki M, Shibata E, Higaki F. Monoamine neurons in the human brain stem ; anatomy, magnetic resonance imaging findings, and clinical implications. Neuroreport 2008 ; 19 : 1649-1654.
 
22) Kashihara K, Shinya T, Higaki F. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. Internal Medicine 2011 ; 50 : 1683-1687.
 
23) Eidelberg D, Dhawan V, Moeller JR, et al. The metabolic landscape of cortico-basal ganglionic degeneration : regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiat 1991 ; 54 : 856-862.
PubMed
24) Blin J, Vidailhet MJ, Pillon B, et al. Corticobasal degeneration : decreased and asymmetrical glucose consumption as studied with PET. Mov Diord 1992 : 7 : 348-354.
PubMed
25) Hosaka K, Ishii K, Sakamoto S, et al. Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration. J Neurol Sci 2002 : 199 : 67-71.
PubMed
26) Walker Z, Gandolfo F, Orini S, et al. Clinical utility of FDG-PET in Parkinson's disease and atypical parkinsonism associated with dementia. Eur J Nuc Med Mol Imaging 2018 ; 45 : 1534-1545.
 
27) Hossain AKMM, Murata Y, Zhang L, et al. Brain perfusion SPECT in patients with corticobasal degeneration : analysis using statistical parametric mapping. Mov Diord 2003 ; 18 : 697-703.
PubMed
28) Mckeith I, O'Braien J, Walker Z, et al. DLB Study Group. Sensitibity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies : a phase III, multicenter study. Lancet Neurol 2007 ; 6 : 305-313.
 
29) Cilia R, Rossi C, Frosini D, et al. Dopamine transporter SPECT imaging in corticobasal syndrome. Plos One 2011 ; 6 : 1-10.
 
30) 日本核医学会・日本脳神経核医学研究会 (編) ; イオフルパン診療ガイドライン 第2版. (http://jsnm.sakura.ne.jp/wp_jsnm/wp-content/themes/theme_jsnm/doc/iofurupan_gl_v2.pdf)
 
31) Kikuchi A, Okamura N, Hasegawa T, et al. In vivo visualization of tau deposition in corticobasal syndrome by 18F-THK5351 PET. Neurology 2016 ; 87 : 2309-2316.
PubMed
32) Day GS, Lim TS, Hassenstab J, et al. Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology 2017 ; 88 : 1273-1281.
PubMed
33) Saito Y, Murayama S. Neuropathology of mild cognitive impairment. Neuropathology 2007 ; 27 : 578-584.
PubMed
34) Boeve BF, Maraganore DM, Parisi JE, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneratoin. Neurology 1999 ; 53 : 795-800.
 
P.151 掲載の参考文献
1) Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002 ; 61 : 935-946.
PubMed
2) Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 ; 80 : 496-503.
PubMed
3) Tsuboi Y, Josephs KA, Boeve BF, et al. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord 2005 ; 20 : 982-988.
PubMed
4) Chand P, Grafman J, Dickson D, et al. Alzheimer's disease presenting as corticobasal syndrome. Mov Disord 2006 ; 21 : 2018-2022.
PubMed
5) Kasanuki K, Josephs KA, Ferman TJ, et al. Diffuse Lewy body disease manifesting as corticobasal syndrome : A rare form of Lewy body disease. Neurology 2018 ; 91 : e268-e279.
PubMed
6) Kouri N, Oshima K, Takahashi M, et al. Corticobasal degeneration with olivopontocerebellar atrophy and TDP-43 pathology : an unusual clinicopathologic variant of CBD. Acta Neuropathol 2013 ; 125 : 741-752.
PubMed
7) Tan CF, Piao YS, Kakita A, et al. Frontotemporal dementia with co-occurrence of astrocytic plaques and tufted astrocytes, and severe degeneration of the cerebral white matter : a variant of corticobasal degeneration? Acta Neuropathol 2005 ; 109 : 329-338.
PubMed
8) Koga S, Sanchez-Contreras M, Josephs KA, et al. Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Mov Disord 2017 ; 32 : 246-255.
PubMed
9) Koga S, Kouri N, Walton RL, et al. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome : a distinct clinicopathologic subtype. Acta Neuropathol 2018 ; 136 : 389-404.
PubMed
10) Tatsumi S, Mimuro M, Iwasaki Y, et al. Argyrophilic grains are reliable disease-specific features of corticobasal degeneration. J Neuropathol Exp Neurol 2014 ; 73 : 30-38.
PubMed
11) Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013 ; 79 : 1094-1108.
 
12) Ono M, Sahara N, Kumata K, et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 2017 ; 140 : 764-780.
PubMed
13) Saijo E, Ghetti B, Zanusso G, et al. Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid. Acta Neuropathol 2017 ; 133 : 751-765.
PubMed
P.154 掲載の参考文献
(1) Marsili L, et al. Parkinsonism and Related Disorders 2016 ; 22 : S96-S100.
PubMed
2) Marsili L, Suppa A, Berardelli A, et al. Therapeutic interventions in parkinsonism : Corticobasal degeneration. Parkinsonism Relat Disord 2016 ; 22 Suppl 1 : S96-S100.
 
(2) Kompoliti K, et al. Arch Neurol 1998 ; 55 : 957-961.
PubMed
(3) Lamb R, et al. Curr Treat Options Neurol 2016 ; 18 : 42.
PubMed
3) Lamb R, Rohrer JD, Lees AJ, et al. Progressive supranuclear palsy and corticobasal degeneration : Pathophysiology and treatment options. Curr Treat Options Neurol 2016 ; 18 : 42.
PubMed
(4) Gomez-Caravaca MT, et al. Neurol Sci 2015 ; 36 : 275-279.
PubMed
4) Okun MS, Tagliati M, Pourfar M, et al. Management of referred deep brain stimulation failures : a retrospective analysis from 2 movement disorders centers. Arch Neurol 2005 ; 62 : 1250-1255.
PubMed
(5) Kovacs T, et al. J Neural Transm 2009 ; 116 : 1631-1634.
 
5) Muller J, Wenning GK, Wissel J, et al. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 2002 ; 249 : 300-304.
PubMed
6) Ali F, Josephs KA. Corticobasal degeneration : key emerging issues. J Neurol 2018 ; 265 : 439-445.
PubMed
(6) Marsili L, Colosimo C. Handbook of Neurological Therapy, OUP, USA, 2015 : 307-313.
 
(7) Karakaya T, et al. Curr Treat Options Neurol 2012 ; 14 : 126-136.
PubMed
7) Kovacs T, Farsang M, Vitaszil E, et al. Levetiracetam reduces myoclonus in corticobasal degeneration : report of two cases. J Neural Transm (Vienna) 2009 ; 116 : 1631-1634.
 
8) Shehata HS, Shalaby NM, Esmail EH, et al. Corticobasal degeneration : clinical characteristics and multidisciplinary therapeutic approach in 26 patients. Neurol Sci 2015 ; 36 : 1651-1657.
PubMed
9) Galpern WR, Lithium in progressive supranuclear palsy and corticobasal degeneration. Movement Disord 2010 ; 25 : S498-S498.
 
10) Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy : a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014 ; 13 : 676-685.
PubMed
P.156 掲載の参考文献
1) Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010 ; 133 : 2045-2057.
PubMed
P.160 掲載の参考文献
1) Foster NL, Wilhelmsen K, Sima AA, et al. Frontotemporal dementia and parkinsonism linked to chromosome 17 : a consensus conference. Ann Neurol 1997 ; 41 : 706-715.
PubMed
2) Forrest SL, Kril JJ, Stevens CH, et al. Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain 2018 ; 141 : 521-534.
PubMed
3) Fujioka S, Van Gerpen JA, Uitti RJ, et al. Familial progressive supranuclear palsy : a literature review. Neurodener Dis 2014 ; 13 : 180-182.
PubMed
4) Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999 ; 8 : 711-715.
PubMed
5) Hoglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genet 2011 ; 43 ; 699-705.
PubMed
6) Melquist S, Craig DW, Huentelman MJ, et al. Identification of a novel risk locus for progressive supranuclear palsy by a pooled genome wide scan of 500,288 single-nucleotide polymorphisms. Am J Hum Genet 2007 ; 80 ; 769-778.
 
7) Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy : The movement disorder society criteria. Mov Disord 2017 ; 32 : 853-864.
PubMed
8) Di Maria E, Tabaton M, Vigo T, et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol 2000 ; 47 : 374-377.
PubMed
9) Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001 ; 56 : 1702-1706.
 
10) Kouri N, Ross OA, Dombroski B, et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun 2015 ; 6 : 7247.
PubMed
11) Kouri N, Carlomagno Y, Baker M, et al. Novel mutation in MAPT exon 13 (p. N410H) causes corticobasal degeneration. Acta Neuropathol 2014 ; 127 : 271-282.
PubMed
12) Fekete R, Bainbridge M, Baizabal-Carvallo JF, et al. Parkinsonism Related Disord Exome sequencing in familial corticobasal degeneration. Parkinsonism Relat Disord 2013 ; 19 : 1049-1052.
 
13) Spina S, Murrell JR, Huey ED, et al. Corticobasal syndrome associated with the A9D Progranulin mutation. J Neuropathol Exp Neurol 2007 ; 66 : 892-900
 
14) Tacik P, DeTure M, Lin WL, et al. A novel tau mutation, p. K317N, causes globular glial tauopathy. Acta Neuropathol 2015 ; 130 : 199-214.
PubMed
15) Tacik P, Sanchez-Contreras M, DeTure M, et al. Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p. P301L mutation, including a patient with globular glial tauopathy. Neuropathol Appl Neurobiol 2017 ; 43 : 200-214.
PubMed
16) Yabe I, Yaguchi H, Kato Y, et al. Mutations in bassoon in individuals with familial and sporadic progressive supranuclear palsy-like syndrome. Sci Rep 2018 ; 8 : 819.
PubMed
P.165 掲載の参考文献
1) Ahmed Z, Bigio EH, Budka H, et al. Globular glial tauopathies (GGT) : consensus recommendations. Acta Neuropathol 2013 ; 126 : 537-544.
PubMed
2) Kovacs GG, Majtenyi K, Spina S, et al. White matter tauopathy with globular glial inclusions : a distinct sporadic frontotemporal lobar degeneration. J Neuropathol Exp Neurol 2008 ; 67 : 963-975.
PubMed
3) Fu YJ, Nishihira Y, Kuroda S, et al. Sporadic four-repeat tauopathy with frontotemporal lobar degeneration, Parkinsonism, and motor neuron disease : a distinct clinicopathological and biochemical disease entity. Acta Neuropathol 2010 ; 120 : 21-32.
PubMed
4) Josephs KA, Katsuse O, Beccano-Kelly DA, et al. Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol 2006 ; 65 : 396-405.
PubMed
P.170 掲載の参考文献
1) Kosaka K, Oyanagi S, Matsushita M, et al. Presenile dementia with Alzheimer-, Pick- and Lewy-body changes. Acta Neuropathol 1976 ; 36 : 221-233.
PubMed
2) McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) : report of the consortium on DLB international workshop. Neurology 1996 ; 47 : 1113-1124.
 
3) McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop : diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999 ; 53 : 902-905.
 
4) McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium. Neurology 2005 ; 65 : 1863-1872.
PubMed
5) 小阪憲司. レビー小体病の概念. 精神科 2016 ; 29 : 1-4.
 
6) 小阪憲司, 神田隆. 1枚のスライド. Brain and Nerve 2013 ; 65 : 1521-1527.
 
7) McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 2017 ; 89 : 88-100.
PubMed
8) 日本神経学会 (監), 「認知症疾患診療ガイドライン」作成委員会 (編). 認知症疾患診療ガイドライン 2017. 医学書院, 2017.
 
9) Ferman TJ, Arvanitakis Z, Fujishiro H, et al. Pathology and temporal onset of visual hallucinations, misperceptions and family misidentification distinguishes dementia with Lewy bodies from Alzheimer's disease. Parkinsonism Relat Disord 2013 ; 19 : 227-231.
 
10) McKeith I, Taylor JP, Thomas A, et al. Revisiting DLB diagnosis : A consideration of prodromal DLB and of the diagnostic overlap with Alzheimer disease. J Geriatr Psychiatry Neurol 2016 ; 29 : 249-253.
PubMed
11) Jicha GA, Schmitt FA, Abner E, et al. Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol Aging 2010 ; 31 : 1805-1813.
PubMed
12) 溝口義人, 門司晃. レビー小体型認知症と他の精神疾患の鑑別. 精神科 2016 ; 29 : 28-31.
 
13) Nishio Y. Visual impairment and false perceptions in dementia with Lewy bodies. Brain and Nerve 2018 ; 70 : 889-904.
PubMed
14) Donadio V, Incensi A, Rizzo G, et al. A new potential biomarker for dementia with Lewy bodies : Skin nerve α-synuclein deposits. Neurology 2017 ; 89 : 318-326.
 
15) Sano K, Atarashi R, Satoh K, et al. Prion-like seeding of misfolded α-synuclein in the brains of dementia with Lewy body patients in RT-QUIC. Mol Neurobiol 2018 ; 55 : 3916-3930.
 
P.176 掲載の参考文献
1) Gomperts SN. Lewy body dementias : Dementia with Lewy bodies and Parkinson disease dementia. Continuum (Minneap Minn) 2016 ; 22 : 435-463.
PubMed
2) Arnaoutoglou NA, O'Brien JT, Underwood BR. Dementia with Lewy bodies-from scientific knowledge to clinical insights. Nat Rev Neurol 2018 ; 15 : 103-112.
 
3) 馬場徹. レビー小体型認知症の臨床. 日本臨床 2018 ; 76 : 124-130.
Medical*Online
4) McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 2017 ; 89 : 88-100.
PubMed
5) Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015 ; 30 : 1591-1601.
PubMed
6) Orimo S, Ozawa E, Nakade S, et al. (123) I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999 ; 67 : 189-194.
PubMed
7) Yoshita M, Arai H, Arai H, et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies : A multicenter study. PLoS One 2015 ; 10 : e0120540.
PubMed
8) Odagiri H, Baba T, Nishio Y, et al. On the utility of MIBG SPECT/CT in evaluating cardiac sympathetic dysfunction in Lewy body diseases. PLoS One 2016 ; 11 : e0152746.
PubMed
9) Yokoi K, Nishio Y, Uchiyama M, et al. Hallucinators tind meaning in noises : pareidolic illusions in dementia with Lewy bodies. Neuropsychologia 2014 ; 56 : 245-254.
 
10) 日本神経学会. 認知症疾患診療ガイドライン 2017. 医学書院, 2017.
 
11) Mori E, Ikeda M, Kosaka K, on behalf of the Donepezil DLBSI. Donepezil for dementia with Lewy bodies : A randomized, placebo-controlled trial. Ann Neurol 2012 ; 72 : 41-52.
 
12) Murata M, Odawara T, Hasegawa K, et al. Adjunct zonisamide to levodopa for DLB parkinsonism : A randomized double-blind phase 2 study. Neurology 2018 ; 90 : e664-e672.
PubMed
P.181 掲載の参考文献
1) Fujimi K, Sasaki K, Noda K, et al. Clinicopathological outline of dementia with Lewy bodies applying the revised criteria : The Hisayama study. Brain Pathol 2008 ; 18 : 317-325.
PubMed
2) Braak H, Del Tredici T, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003 ; 24 : 197-211.
 
3) Halliday G, Hely M, Reid W, et al. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008 ; 115 : 409-415.
PubMed
4) Fujishiro H, Nakamura S, Sato K, et al. Prodromal dementia with Lewy bodies. Geriatr Gerontol Int 2015 ; 15 : 817-826.
PubMed
5) 小阪憲司, 松下正明, 小柳新策, Mehraein P. "Lewy小体病" の臨床神経病理学的研究. 精神神経誌 1980 ; 82 : 292-311.
 
6) Frigerio R, Fujishiro H, Ahn TB, et al. Incidental Lewy body disease : do some cases represent preclinical dementia with Lewy bodies? Neurobiol Aging 2011 ; 32 : 857-863.
PubMed
7) Fujishiro H, Ferman TJ, Boeve BF, et al. Validation of the Neuropathologic Criteria of the Third Consortium for Dementia with Lewy Bodies for Prospectively Diagnosed Cases. J Neuropathol Exp Neurol 2008 ; 67 : 649-656.
 
8) McKeith IG, Bradley B, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies : fourth report of the DLB Consortium. Neurology 2017 ; 65 : 1863-1872.
 
9) Kosaka K. Diffuse Lewy body disease in Japan. J Neurol 1990 ; 237 : 197-204.
PubMed
10) Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. 2015 ; 30 : 1591-1599.
PubMed
P.187 掲載の参考文献
1) Adams RD, Fisher CM, Hakim S, et al. Symptomatic occult hydrocephalus with "normal" cerebrospinal-fluid pressure. A treatable syndrome. N Engl J Med 1965 ; 273 : 117-126.
PubMed
2) Ishikawa M. Clinical guidelines for idiopathic normal pressure hydrocephalus. Neurol Med Chir (Tokyo) 2004 ; 44 : 222-223.
PubMed
3) Mori E, Ishikawa M, Kato T, et al. Guidelines for management of idiopathic normal pressure hydrocephalus : Second edition. Neurol Med Chir (Tokyo) 2012 ; 52 : 775-809.
PubMed
4) Hashimoto M, Ishikawa M, Mori E, et al. Diagnosis of idiopathic normal pressure hydrocephalus is supported by mri-based scheme : A prospective cohort study. Cerebrospinal Fluid Res 2010 ; 7 : 18.
PubMed
5) Kazui H, Miyajima M, Mori E, et al. Lumboperitoneal shunt surgery for idiopathic normal pressure hydrocephalus (sinphoni-2) : An open-label randomised trial. The Lancet Neurology 2015 ; 14 : 585-594.
PubMed
6) Relkin N, Marmarou A, Klinge P, et al. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 2005 ; 57 : S4-16 ; discussion ii-v.
 
7) Tanaka N, Yamaguchi S, Ishikawa H, et al. Prevalence of possible idiopathic normal-pressure hydrocephalus in Japan : The osaki-tajiri project. Neuroepidemiology 2009 ; 32 : 171-175.
PubMed
8) Iseki C, Takahashi Y, Wada M, et al. Incidence of idiopathic normal pressure hydrocephalus (inph) : A 10-year follow-up study of a rural community in Japan. J Neurol Sci 2014 ; 339 : 108-112.
PubMed
9) Nakashita S, Wada-Isoe K, Uemura Y, et al. Clinical assessment and prevalence of parkinsonism in Japanese elderly people. Acta Neurol Scand 2016 ; 133 : 373-379.
PubMed
10) Jaraj D, Rabiei K, Marlow T, et al. Prevalence of idiopathic normal-pressure hydrocephalus. Neurology 2014 ; 82 : 1449-1454.
PubMed
11) Kubo Y, Kazui H, Yoshida T, et al. Validation of grading scale for evaluating symptoms of idiopathic normal-pressure hydrocephalus. Dement Geriatr Cogn Disord 2008 ; 25 : 37-45.
PubMed
12) Ohmichi T, Kondo M, Itsukage M, et al. Usefulness of the convexity apparent hyperperfusion sign in 123 I-iodoamphetamine brain perfusion spect for the diagnosis of idiopathic normal pressure hydrocephalus. J Neurosurg 2018 ; 130 : 398-405.
 
13) Cushing H. Studies on the cerebro-spinal fluid : I. Introduction. J Med Res 1914 ; 31 : 1-19.
PubMed
14) Weller RO, Djuanda E, Yow HY, et al. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 2009 ; 117 : 1-14.
PubMed
15) Oreskovic D, Klarica M. The formation of cerebrospinal fluid : Nearly a hundred years of interpretations and misinterpretations. Brain Res Rev 2010 ; 64 : 241-262.
PubMed
16) Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates csf flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med 2012 ; 4 : 147ra111.
 
17) Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015 ; 523 : 337-341.
PubMed
P.190 掲載の参考文献
1) Jusue-Torres I, Jeon LH, Sankey EW, et al. A novel experimental animal model of adult chronic hydrocephalus. Neurosurg 2016 ; 79 : 746-756.
 
2) Akiguchi I, Ishii M, Watanabe Y, et al. Shunt-responsive parkinsonism and reversible white matter lesions in patients with idiopathic NPH. J Neurol 2008 ; 255 : 1392-1399.
PubMed
3) Racette BA, Esper GJ, Antenor J, et al. Pathophysiology of parkinsonism due to hydrocephalus. J Neurol Neurosurg Psychiatry 2004 ; 75 : 1617-1619.
PubMed
4) Ishikawa M. Clinical guidelines for idiopathic normal pressure hydrocephalus. Neurol Med Chir (Tokyo) 2004 ; 44 : 222-223.
PubMed
5) Leinonen V, Koivisto AM, Savolainen S, et al. Post-mortem findings in 10 patients with presumed normal-pressure hydrocephalus and review of the literature. Neuropathol Appl Neurobiol 2012 ; 38 : 72-86.
PubMed
6) Kang K, Yoon U, Hong J, et al. Amyloid deposits and idiopathic normal-pressure hydrocephalus : An 18F-florbetaben study. Eur Neurol 2018 ; 79 : 192-199.
 
7) Khasawneh AH, Garling RJ, Harris CA. Cerebrospinal fluid circulation : What do we know and how do we know it? Brain Circ 2018 ; 4 : 14-18.
PubMed
8) Carare RO, Bernardes-Silva M, Newman TA, et al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries : significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 2008 ; 34 : 131-144.
 
9) Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 2012 ; 4 : 147ra111.
 
10) Ringstad G, Vatnehol SAS, Eide PK, et al. Glymphatic MRI in idiopathic normal pressure hydrocephalus. Brain 2017 ; 140 : 2691-2705.
PubMed
11) Hasan-Olive MM, Enger R, Hansson HA, et al. Loss of perivascular aquaporin-4 in idiopathic normal pressure hydrocephalus. Glia 2018 ; 67 : 91-100.
PubMed
12) Ishikawa M, Oowaki H, Takezawa M, et al. Disproportionately enlarged subarachnoid space hydrocephalus in idiopathic normal-pressure hydrocephalus and its implication in pathogenesis. Acta Neurochir Suppl 2016 ; 122 : 287-290.
PubMed
13) Tullberg M1, Hultin L, Ekholm S, et al. White matter changes in normal pressure hydrocephalus and Binswanger disease : specificity, predictive value and correlations to axonal degeneration and demyelination. Acta Neurol Scand 2002 ; 105 : 417-426.
 
14) 宮田元, 大浜栄作. 特発性正常圧水頭症 (iNPH) の神経病理. 老年期認知症研究会誌 2013 ; 20 : 6-9.
 
15) Brautigam K, Vakis A, Tsitsipanis C. Pathogenesis of idiopathic normal pressure hydrocephalus : A review of knowledge. J Clin Neurosci 2019 ; 61 : 10-13.
PubMed

III 病態解明と治療法の確立に向けて

P.197 掲載の参考文献
1) Poewe W, Seppi K, Fitzer-Attas CJ, et al. Rasagiline-for-MSA investigators. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy : a randomised, placebo-controlled trial. Lancet Neurol 2015 ; 14 : 145-152.
PubMed
2) Low PA, Robertson D, Gilman S, et al. Efficacy and safety of rifampicin for multiple system atrophy : a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014 ; 13 : 268-275.
PubMed
3) Lee PH, Lee JE, Kim HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012 ; 72 : 32-40.
PubMed
4) Novak P, Williams A, Ravin P, et al. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol 2012 ; 12 : 131.
PubMed
5) Friess E, Kuempfel T, Modell S, et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord 2006 ; 12 : 432-437.
PubMed
6) Levin J, Maas S, Schuberth M, et al. PROMESA study group, Giese A, Botzel K, Hoglinger G. The PROMESA-protocol : progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. J Neural Transm (Vienna) 2016 ; 123 : 439-445.
 
7) Apetauerova D, Scala SA, Hamill RW, et al. CoQ10 in progressive supranuclear palsy : A randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm 2016 ; 3 : e266.
PubMed
8) Nuebling G, Hensler M, Paul S, et al. PROSPERA : a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J Neurol 2016 ; 263 : 1565-1574.
PubMed
9) Stamelou M, Schope J, Wagenpfeil S, et al. AL-108-231 Investigators, Tauros Investigators, and MDS-Endorsed PSP Study Group. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. Mov Disord. 2016 ; 31 : 742-747.
 
10) Boxer AL, Lang AE, Grossman M, et al. AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy : a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014 ; 13 : 676-685.
PubMed
11) Tolosa E, Litvan I, Hoglinger GU, et al. TAUROS Investigators. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 2014 ; 29 : 470-478.
 
12) Leclair-Visonneau L, Rouaud T, Debilly B, et al. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin Neurol Neurosurg 2016 ; 146 : 35-39.
PubMed
13) Canesi M, Giordano R, Lazzari L, et al. Finding a new therapeutic approach for no-option Parkinsonisms : mesenchymal stromal cells for progressive supranuclear palsy. J Transl Med 2016 ; 14 : 127.
PubMed
14) West T, Hu Y, Verghese PB, et al. Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer's disease and other tauopathies. J Prev Alzheimers Dis 2017 ; 4 : 236-241.
PubMed
P.203 掲載の参考文献
1) Hasegawa T. Pathogenesis of multiple system atrophy. Neurol Clin Neurosci 2013 ; 1 : 189-194.
 
2) Stefanova N. Translational therapies for multiple system atrophy : Bottlenecks and future directions. Auton Neurosci 2018 ; 211 : 7-14.
PubMed
3) Whittaker HT, Qui Y, Bettencourt C, et al. Multiple system atrophy : genetic risks and alpha-synuclein mutations. F1000Research 2017 ; 6 : 2072.
PubMed
4) Mittal S, Bjornevik K, Im DS, et al. Beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson's disease. Science 2017 ; 357 : 891-898.
PubMed
5) Levin J, Maass S, Schuberth M, et al. The PROMESA-protocol : progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. Journal of Neural Transmission (Vienna, Austria : 1996) 2016 ; 123 : 439-445.
 
6) Sacca F, Marsili A, Quarantelli M, et al. A randomized clinical trial of lithium in multiple system atrophy. J Neurol 2013 ; 260 : 458-461.
PubMed
7) Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders : The NNIPPS Study. Brain 2009 ; 132 : 156-171.
PubMed
8) Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson disease : A randomized clinical trial. JAMA Neurol 2018 ; 75 : 1206-1214.
PubMed
P.208 掲載の参考文献
1) Morris, M, Maeda, S, Vossel, K, et al. The many faces of Tau. Neuron 2011 : 70 : 410-426.
PubMed
2) Spillantini MG, Murrell JR, Goedert M, et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 1998 ; 95 : 7737-7741.
 
3) Poorkaj P, Bird TD, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementa. Ann Neurol 1998 ; 43 : 815-825.
 
4) Hutton M, Lendon CL, Rizzu P, et al. Association of mis-sense and 5'-splice-site mutations in tau with the inher-ited dementia FTDP-17. Nature 1998 ; 393 : 702-705.
 
5) Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathologica 2016 ; 131 : 267-280.
PubMed
6) Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009 ; 11 : 909-913.
PubMed
7) Nonaka T, Watanabe ST, Iwatsubo T, et al. Seeded aggregation and toxicity of α-synuclein and tau : cellular models of neurodegenerative diseases. J Biol Chem 2010 ; 285 : 34885-34898.
 
8) Narasimhan S, Guo JL, Changolkar L, et al. Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain. J Neurosci 2017 ; 37 : 11406-11423.
 
9) Fitzpatrick AWP, Falcon B, He S, et al. Cryo-EM structures of tau filaments from Alzheimer's disease. Nature 2017 ; 547 : 185-190.
PubMed
10) Falcon B, Zhang W, Murzin AG, et al. Structures of filaments from Pick's disease reveal a novel tau protein fold. Nature 2018 ; 561 : 137-140.
PubMed
11) Asai H, Ikezu S, Tsunoda S, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 2015 ; 18 : 1584-1593.
PubMed
12) Bussian TJ, Aziz A, Meyer CF, et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 2018 ; 562 : 578-582.
PubMed
13) Tatebe H, Kasai T, Ohmichi T, et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology : pilot case-control studies including patients with Alzheimer's disease and down syndrome. Mol Neurodegener 2017 ; 12 : 63.
 
P.214 掲載の参考文献
1) Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006 ; 442 : 916-919.
PubMed
2) Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006 ; 442 : 920-924.
PubMed
3) Gass J, Cannon A, Mackenzie IR, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 2006 ; 15 : 2988-3001.
 
4) Mukherjee O, Pastor P, Cairns NJ, et al. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol 2006 ; 60 : 314-322.
PubMed
5) Brouwers N, Nuytemans K, van der Zee J, et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol 2007 ; 64 : 1436-1446.
 
6) Leverenz J. B, Yu CE, Montine TJ, et al. A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. Brain 2007 ; 130 : 1360-1374.
PubMed
7) Rovelet-Lecrux A, Deramecourt V, Legallic S, et al. Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. Neurobiol Dis 2008 ; 31 : 41-45.
PubMed
8) Kelley BJ, Haidar W, Boeve BF, et al. Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging 2009 ; 30 : 739-751.
PubMed
9) Hosokawa M, Kondo H, Serrano GE, et al. Accumulation of multiple neurodegenerative disease-related proteins in familial frontotemporal lobar degeneration associated with granulin mutation. Sci Rep 2017 ; 7 : 1513.
PubMed
10) Carecchio M, Galimberti D, Fenoglio C, et al. Evidence of pre-synaptic dopaminergic deficit in a patient with a novel progranulin mutation presenting with atypical parkinsonism. J Alzheimers Dis 2014 ; 38 : 747-752.
 
11) Chang KH, Lee GC, Huang CC, et al. Genetic and functional characters of GRN p. T487I mutation in Taiwanese patients with atypical parkinsonian disorders. Parkinsonism Relat Disord 2018 ; 51 : 61-66.
PubMed
12) Masellis M, Momeni P, Meschino W, et al. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain 2006 ; 129 : 3115-3123.
PubMed
13) Spina S, Murrell JR, Huey ED, et al. Corticobasal syndrome associated with the A9D Progranulin mutation. J Neuropathol Exp Neurol 2007 ; 66 : 892-900.
PubMed
14) Guerreiro RJ, Santana I, Bras JM, et al. Novel progranulin mutation : screening for PGRN mutations in a Portuguese series of FTD/CBS cases. Mov Disord 2008 ; 23 : 1269-1273.
 
15) Benussi L, Binetti G, Sina E, et al. A novel deletion in progranulin gene is associated with FTDP-17 and CBS. Neurobiol Aging 2008 ; 29 : 427-435.
PubMed
16) Dopper EG, Seelaar H, Chiu WZ, et al. Symmetrical corticobasal syndrome caused by a novel C. 314dup progranulin mutation. J Mol Neurosci 2011 ; 45 : 354-358.
 
17) Rademakers R, Eriksen JL, Baker M, et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet 2008 ; 17 : 3631-3642.
 
18) Jasinska-Myga B, Wider C, Opala G, et al. GRN 3'UTR+78 C > T is not associated with risk for Parkinson's disease. Eur J Neurol 2009 ; 16 : 909-911.
 
19) Chang KH, Chen CM, Chen YC, et al. Association between GRN rs5848 polymorphism and Parkinson's disease in Taiwanese population. PLoS One 2013 ; 8 : e54448.
PubMed
20) Mateo I, Gonzalez-Aramburu I, Pozueta A, et al. Reduced serum progranulin level might be associated with Parkinson's disease risk. Eur J Neurol 2013 ; 20 : 1571-1573.
PubMed
21) Tartaglia MC, Sidhu M, Laluz V, et al. Sporadic corticobasal syndrome due to FTLD-TDP. Acta Neuropathol 2010 ; 119 : 365-374.
PubMed
22) Peng G, Liu P, He F, et al. Posterior cortical atrophy as a primary clinical phenotype of corticobasal syndrome with a progranulin gene rs5848 TT genotype. Orphanet J Rare Dis 2016 ; 11 : 13.
PubMed
23) Sieben A, Van Mossevelde S, Wauters E, et al. Extended FTLD pedigree segregating a Belgian GRN-null mutation : neuropathological heterogeneity in one family. Alzheimers Res Ther 2018 ; 10 : 7.
PubMed
24) Tanaka Y, Matsuwaki T, Yamanouchi K, et al. Exacerbated inflammatory responses related to activated microglia after traumatic brain injury in progranulin-deficient mice. Neuroscience 2013 ; 231 : 49-60.
PubMed
25) Hosokawa M, Tanaka Y, Arai T, et al. Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer's disease model mice. Exp Anim 2018 ; 67 : 63-70.
PubMed
26) Tanaka Y, Suzuki G, Matsuwaki T, et al. Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. Hum Mol Genet 2017 ; 26 : 969-988.
PubMed
27) Arrant AE, Onyilo VC, Unger DE, et al. Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis. J Neurosci 2018 ; 38 : 2341-2358.
PubMed
28) Sha SJ, Miller ZA, Min SW, et al. An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. Alzheimers Dement (NY) 2017 ; 3 : 507-512.
 
29) Lee WC, Almeida S, Prudencio M, et al. Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency. Hum Mol Genet 2014 ; 23 : 1467-1478.
PubMed
P.220 掲載の参考文献
1) Virgilio AD, Greco A, Fabbrini G, et al. Parkinson's disease : Autoimmunity and neuroinflammation. Autoimmunity Reviews 2016 ; 15 : 1005-1011.
 
2) He Y, Le WD, Appel SH. Role of FCγ receptors in nigral cell injury induced by Parkinson's disease immunoglobulin injection into mouse substantia nigra. Exp Neurol 2002 ; 176 : 322-327.
 
3) Liu B, Gao HM, Hong JS. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injury : role of neuroinflammation. Environ Health Perspect 2003 ; 111 : 1065-1073.
PubMed
4) Fiszer U, Mix E, Fredrikson S, et al. Gamma delta+ T cells are increased in patients with Parkinson's disease. J Neurol Sci 1994 ; 121 : 39-45.
PubMed
5) Brochard V, Combadiere B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009 ; 119 : 182-192.
 
6) Cebrian C, Zucca FA, Mauri P, et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun 2014 ; 5 : 3633.
 
7) Sulzer D, Alcalay RN, Garretti F, et al. T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature 2017 ; 546 : 656-661.
 
8) Orr CF, Rowe DB, Mizuno Y, et al. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005 ; 128 : 2665-2674.
PubMed
9) Graham DG. On the origin and significance of neuromelanin. Arch Pathol Lab Med 1979 ; 103 : 359-362.
PubMed
10) Oberlander U, Pletinckx K, Dohler A, et al. Neuromelanin is an immune stimulator for dendritic cells in vitro. BMC Neurosci 2011 ; 12 : 116.
PubMed
11) Carvey PM, McRae A, Lint TF, et al. The potential use of dopamine neuron antibody and a striatal-derived neurotropic factor as diagnostic markers in Parkinson's disease. Neurology 1991 ; 41 : 53-58.
 
12) LeWD, Rowe DB, Jankovic J, et al. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol 1999 ; 56 : 194-200.
 
13) Chen S, Le WD, Xie WJ, et al. Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol 1998 ; 55 : 1075-1080.
 
14) Brudek T, Winge K, Folke J, et al. Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy ; a step towards immunotherapeutic strategies. Mol Neurodegener 2017 ; 12 : 44.
PubMed
15) Damato V, Balint B, Kienzler AK, et al. The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders. Mov Disord 2018 ; 33 : 1376-1389.
PubMed
16) Sabater L, Gaig C, Gelpi E, et al. A novel non-rapideye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5 : a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014 ; 13 : 575-586.
 
17) Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology 2017 ; 88 : 1736-1743.
PubMed
P.224 掲載の参考文献
1) Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989 ; 94 : 79-100.
PubMed
2) Spillantini MG, Crowther RA, Jakes R, et al. Filamentous a-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998 ; 251 : 205-208.
PubMed
3) Wakabayashi K, Yoshimoto M, Tsuji S, et al. alpha-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998 ; 249 : 180-182.
PubMed
4) Peng C, Gathagan RJ, Covell DJ, et al. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. Nature 2018 ; 557 : 558-563.
 
5) Yazawa I, Giasson BI, Sasaki R, et al. Mouse model of multiple system atrophy : alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005 : 45 ; 847-859.
PubMed
6) Nakayama K, Suzuki Y, Yazawa I. Microtubule depolymerization suppresses alpha-synuclein accumulation in a mouse model of multiple system atrophy. Am J Pathol 2009 ; 174 : 1471-1480.
 
7) Suzuki Y, Jin C, Yazawa I. Cystatin C triggers neuronal degeneration in a model of multiple system atrophy. Am J Pathol 2014 ; 184, 790-799.
 
8) Watts JC, Giles K, Oehler A, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci USA 2013 ; 26 : 19555-19560.
 
9) Kahle PJ, Neumann M, Ozmen L, et al. Hyperphosphorylation and insolubility of a-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002 ; 3 : 583-588.
PubMed
10) Shults CW, Rockenstein E, Crews L, et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human a-synuclein under oligodendrocyte promoter : implications for multiple system atrophy. J Neurosci 2005 ; 25 : 10689-10699.
 
11) Mandel RJ, Marmion DJ, Kirik D, et al. Novel oligodendroglial alpha synuclein viral vector models of alpha synuclein viral vector models of multiple system atrophy : studies in rodents and nonhuman primates. Acta Neuropathol Commun 2017 ; 5 : 47.
PubMed
12) Nakayama K, Suzuki Y, Yazawa I. Binding of neuronal alpha-synuclein to beta-3 tubulin and accumulation in a mouse model of multiple system atrophy. Biochem Biophys Res Commun 2012 ; 417 : 1170-1175.
 
13) Suzuki Y, Jin C, Iwase T, et al. beta-III Tubulin fragments inhibit alpha-synuclein accumulation in models of multiple system atrophy. J Biol Chem 2014 ; 289 : 24374-24382.
PubMed
14) Ubhi K, Rockenstein E, Mante M, et al. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 2008 ; 19 : 1271-1276.
 
15) Kaji S, Maki T, Kinoshita H, et al. Pathological endogenous α-synuclein accumulation in oligodendrocyte precursor cells potentially induces inclusions in multiple system atrophy. Stem Cell Reports 2018 ; 10 : 356-365.
 
P.231 掲載の参考文献
1) Dickson DW. Neuropathological diagnosis of Alzheimer's disease : a perspective from longitudinal clinicopathological studies. Neurobiology of Aging 1997 ; 18 : S21-26.
PubMed
2) Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology 2004 ; 55 : 306-319.
PubMed
3) Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001 ; 24 : 1121-1159.
PubMed
4) Goedert M, Yamaguchi Y, Mishra SK, et al. Tau filaments and the development of positron emission tomography tracers. Frontiers in Neurology 2018 ; 9 : 70.
PubMed
5) Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998 ; 393 : 702-705.
PubMed
6) Poorkaj P, Bird TD, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Annals of Neurology 1998 ; 43 : 815-825.
PubMed
7) Ebneth A, Godemann R, Stamer K, et al. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum : implications for Alzheimer's disease. The Journal of Cell Biology 1998 ; 143 : 777-794.
PubMed
8) Allen B, Ingram E, Takao M, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002 ; 22 : 9340-9351.
PubMed
9) Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007 ; 53 : 337-351.
 
10) Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005 ; 309 : 476-481.
 
11) Andorfer C, Kress Y, Espinoza M, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 2003 ; 86 : 582-590.
PubMed
12) Sahara N, Shimojo M, Ono M, et al. In vivo tau imaging for a diagnostic platform of tauopathy using the rTg4510 mouse line. Frontiers in Neurology 2017 ; 8 : 663.
PubMed
13) Goodwin LO, Splinter E, Davis TL, et al. Large-scale discovery of mouse transgenic integration sites reveals frequent structural variation and insertional mutagenesis. Genome Res 2019 [Epub ahead of print]
 
14) Yan H, Pablo JL, Wang C, et al. FGF14 modulates resurgent sodium current in mouse cerebellar Purkinje neurons. eLife 2014 ; 3 : e04193.
PubMed
P.238 掲載の参考文献
1) Stefanova N, Wenning GK. Review : Multiple system atrophy : emerging targets for interventional therapies. Neuropathol Appl Neurobiol 2016 ; 42 : 20-32.
PubMed
2) Low PA, Robertson D, Gilman S, et al. Efficacy and safety of rifampicin for multiple system atrophy : a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014 ; 13 : 268-275.
PubMed
3) Desmarais P, Rohrer JD, Nguyen QD, et al. Therapeutic trial design for frontotemporal dementia and related disorders. J Neurol Neurosurg Psychiatry 2018. [Epub ahead of print]
 
4) Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy : a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014 ; 13 : 676-685.
PubMed
5) Katsuno M, Tanaka F, Sobue G. Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2014 ; 83 : 329-335.
 
6) Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease : a systematic review and meta-analysis. Neurology 2014 ; 83 : 253-260.
PubMed
7) 国立精神・神経医療研究センター : Remudy (ジストロフィノパチー患者さまご登録サイト). (http://www.remudy.jp/dystrophinopathy/index.html)
 
8) 日本医療研究開発機構 : オレンジレジストリ. (http://www.ncgg.go.jp/orange/index.html)
 
9) 厚生労働省 : 医薬品の製造販売後データベース調査における信頼性担保における留意点. (https://www.pmda.go.jp/files/000223003.pdf)
 
10) AMED医薬品等規制調和・評価研究事業「患者レジストリーデータを用い, 臨床開発の効率化を目指すレギュラトリーサイエンス研究」班 信頼性分担班. 「患者レジストリーデータを医薬品等の承認申請資料等として活用する場所におけるデータの信頼性担保に関する提言」作成の経緯. 日本臨床試験学会雑誌 (投稿中).
 

書評

最近チェックした商品履歴

Loading...